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ABSTRACT 
The significant applications of fluorinated molecules in the pharmaceutical, agrochemical, 
and material sciences make them attractive synthetic targets. Difluoromethylation methods are of 
exceptional value and a limited number of techniques are available to perform that transformation. 
The primary method for introducing CF2 groups is through the use of difluoroenolates. 
Difluoroenolates can be generated from α-keto pentafluoro gem-diols under mild conditions. The 
process involves the cleavage of carbon-carbon bond and the release of trifluoroacetate. The 
release of trifluoroacetate is a versatile method to generate fluorinated molecules. We explored the 
utility of this method in generating various fluorinated moieties including α,α-difluoroketones, α-
deutero-α,α-difluoroketones, α,α-difluoromethyl sulfones, α-deutero-α,α-difluoromethyl sulfones, 
monofluoro β-hydroxy ketones and α,α-difluorohalohydrins. 
We also endeavored to design and synthesize fluorinated molecules for biological 
applications. Our efforts were aimed at the use of a novel fluorinated β-hydroxy ketone scaffold 
developed in our lab to develop new agonists of the GABAB receptor. The value of GABAB 
agonists as muscle relaxants is well established, and interest in these agonists has been rekindled 
due to reports of new applications in managing drug and alcohol tolerance. We have developed 
several new analogues, characterized new structure-activity relationships of the fluorinated β-
hydroxy ketone scaffold, and identified more active agents. 
We are also interested in using fluorine as a tag to track anti-body drug conjugates (ADCs). 
The chemistry of ADC linkers has attracted a lot of interest recently. The cleavage of the linker is 
essential for the function of ADCs and in addition to this traditional role, linkers can provide a 
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handle for tagging ADCs. The incorporation of fluorine into linkers minimally affects the sterics 
of the linker owing to the small size of fluorine atom while at the same time provides a tractable 
tag. A fluorinated ADC linker has been designed and its synthesis was explored. 
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CHAPTER 1 
INTRODUCTION 
1.1 Fluorine in Medicinal Chemistry 
Fluorine is rarely found in biological systems, nonetheless it’s been extensively used by 
medicinal and pharmaceutical chemists owing to its unique properties. Five of the ten bestselling 
small molecule drugs in 2016 are fluorinated molecules; namely Harvoni®, Advair®, Januvia®, 
Truvada®, and Crestor® (Figure 1.1).1 In addition to its distinct role in pharmaceutical products, 
fluorine has significant applications in medical imaging,2 material science,3 and agrochemicals.4 
While monofluorinated and trifluorinated molecules have found widespread applications, gem-
difluorinated molecules are not as prevalent. However, several drugs on the market are gem-
difluorinated (Figure 1.2), demonstrating the significance of this group. 
  
Figure 1.1. Structures of the top five fluorinated drugs: Harvoni®, Advair®, Truvada®, 
Januvia®, and Crestor® 
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Figure 1.2. Structures of gem-difluorinated drugs: Zioptan, Protonix, Gemzar, and Selzentry 
 
1.1.2. Fluorination Reagents and Fluorinated Building Blocks 
The incorporation of fluorine into organic molecules remains a synthetic challenge despite 
the many advances in the field. The synthesis of fluorinated compounds is typically accomplished 
through direct fluorination or the incorporation of fluorinated building blocks. Harsh reagents like 
fluorine and hydrogen fluoride gases were the mainstay of the fluorination field for a long time. 
They remain relevant today as most of the currently used fluorinating reagents require the use of 
these gasses for their synthesis. Attempts to minimize the use of these reagents led to the 
development of more stable fluorine sources. For example, the HF complex with pyridine known 
as Olah’s reagent is a stabilized, less volatile form of HF; nonetheless, it’s still a corrosive and 
toxic reagent due to the presence of HF.5 Xenon difluoride is used as a more stable alternative to 
F2 gas, however it’s a highly reactive reagent and intolerant to many types of substrate intolerance.6  
The field of fluorination has seen a lot of progress with several new fluorinating reagents 
being commercialized; these reagents can be classified as nucleophilic or electrophilic sources of 
fluorine (Figure 1.3 (a)). Nucleophilic fluorinating reagents, such DAST7 and Deoxo-Fluor,8 are 
generally aminosulfur trifluorides that deoxyfluorinate or dethiofluorinate carbonyl, hydroxyl, 
thiocarbonyl, or sulfide groups. On the other hand, electrophilic fluorinating reagents, such as 
Selectfluor9 and NFSI,10 are N–fluoro compounds that fluorinate nucleophiles like enolates, enol 
ethers, and electron-rich aromatic rings.  
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Figure 1.3. (a) Fluorination reagents, (b) difluoromethylation and trifluoromethylation reagents, 
(c) fluorinated building blocks 
 
Moreover, difluoromethylating and trifluoromethylating reagents, such as the Ruppert-
Prakash reagent11 and the Colby reagent,12 can be utilized to introduce a CF2H or a CF3 group 
directly (Figure 1.3 (b)). These reagents help overcome issues of incompatibility with fluorinating 
reagents as well as improve atom economy. On the other hand, the synthesis of fluorinated organic 
molecules can be accomplished by utilizing fluorinated building blocks (Figure 1.3 (c)). This 
approach helps address issues of over- and under-fluorination and functional group tolerance of 
fluorination reagents, moreover it provides a cheaper alternative to using the expensive 
fluorination reagents. Despite the abundance of commercially available fluorinated building 
blocks, they are especially limited in the context of internal fluorinated groups like the 
difluoromethylene group.      
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1.1.3. Fluoroenolates 
Installing a difluoromethylene subunit is relatively more challenging than 
monofluoronation or trifluoromethylation. Nonetheless, compounds containing a 
difluoromethylene group are beneficial intermediates in the synthesis of pharmaceuticals and 
agrochemicals. α,α-Difluorinated ketones are privileged moieties that have shown enzymatic 
inhibition activity on various targets.13-19 The preparation of these types of ketones can be 
accomplished mainly by one of two methods: direct fluorination or using a fluorinated synthon. 
The synthon method typically involves fluoroenolates. Fluoroenolates can be trapped as 
difluoroenoxysilanes, fluoroenol ethers, fluoroenol phosphates, or fluoroenol sulfonates then used 
in subsequent reactions; however, this strategy can be time consuming as well as lacking in atom 
economy. On the other hand, metal fluoroenolates can be generated in situ and used directly in the 
reaction without the need for trapping and isolation. A comprehensive review of fluorinated enol 
ethers was published in 2015.20  
Metal fluoroenolates are generally generated through nucleophilic displacement of a 
leaving group at the α-position of a carbonyl group. Prominent examples of this transformation 
include Reformatsky-type reactions and copper-mediated coupling reactions (Scheme 1.1 (a–c)). 
An alternative strategy to access metal enolates is through carbon-carbon bond cleavage in 
decarboxylative reactions and trifluoroacetate-release reactions (Scheme 1.1 (d, e)). 
5 
 
 
Scheme 1.1. Reactions employing transient fluoroenolates 
1.2. Reformatsky-type Reactions 
The Reformatsky reaction is one of the earliest examples of organometallic chemistry. It 
was first reported in 1887 and had been used extensively ever since as an effective C-C bond 
forming reaction.21 It is one of the most popular methodologies for the formation of α-fluorinated 
carbonyl compounds. In this reaction, metal enolates (usually zinc) are generated from α-
halocarbonyl compounds under neutral conditions.  The fact that no base or acid is required for 
the enolate generation is one of the appeals of this technique. In addition to the versatility of the 
reaction due to the variety of electrophiles compatible with the reaction conditions, its applicability 
to inter- and intra-molecular transformations, and the low cost of the reagents used.22 Nonetheless, 
the Reformatsky reaction is limited by its relatively low yields and the difficulty of development 
of stereoselective variants of the reaction.23   
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In 1955, McBee and co-workers were the first to apply the Reformatsky reaction to α-
fluorinated substrates, namely ethyl bromofluoroacetate, using zinc dust under reflux.24 This report 
prompted a cascade of developments in this field, limited at first to monofluorinated substrates and 
later expanded to difluorinated substrates. In 1984, Hallinan and Fried applied this reaction to ethyl 
α,α-bromodifluoroacetate using similar conditions to the McBee report.25 A few years later, 
Kuroboshi and Ishihara used zinc and copper chloride to react bromodifluoroketones with 
aldehydes, whereas to effect the same reaction with ketones, zinc and silver acetate were 
required.26 Many variations of the reaction have been reported; these include using different metals 
such indium27-30 as a catalyst or using different solvents including water.31 In other variants, 
benzotriazole substituted methyl amines can act as iminium cation precursors. In these reactions, 
benzotriazole serves as a leaving group and CH2-NR2 group is added to difluoroacetate.
32-36 
The Reformatsky reaction is used to provide gem-difluorocarbonyl compounds as a starting 
point for many synthesized routes, ranging from enzyme-catalyzed37 and biocatalysis reactions38 
to cross-coupling39 and rearrangement reactions.40 Methodologies employing Reformatsky 
reaction were also developed to access fluorinated heterocycles (Scheme 1.2 (a)).41-45 An 
interesting example of these methodologies comes from the Gouverneur group where following a 
Reformatsky reaction to construct gem-difluorinated β-hydroxyynones, a gold-catalyzed 6-endo-
dig cyclization produced difluorodihydropyranones in good yields (Scheme 1.2 (b)).41 
7 
 
 
Scheme 1.2. Reformatsky reaction to access fluorinated heterocycles 
 
1.2.1. Biologically Relevant Applications 
Being a reliable and well established difluoroacetylation method, the Reformatsky reaction 
has been employed extensively in the synthesis of biologically relevant molecules, varying from 
probes46 to receptor modulators47 and enzyme inhibitors.36, 48-53 An interesting example of these 
applications is a report by Qing and co-workers in which the gem-difluorinated carbocyclic 
nucleosides 1.3, 1.4, and 1.5 are synthesized as potential highly stable antiviral and anticancer 
agents.54-55 The key step in the synthesis of these carbocyclic nucleosides is a diastereoselective 
Reformatsky-Claisen rearrangement; a zinc-mediated [3,3]-sigmatropic rearrangement (Scheme 
1.3 (a)).54 Similarly, Tanaka and co-workers used Reformatsky reactions to introduce fluorine in 
their synthetic route of gem-difluorocyclobutane analogue 1.8 (Scheme 1.3 (b)).56 
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Scheme 1.3. Carbocyclic nucleoside synthesis using Reformatsky-Claisen rearrangement 
 
The Reformatsky reaction was used in the total synthesis of difluorinated analogue of 
ripostatin A to gain insight into the active form of ripoostatins (Scheme 1.4). Ripostatin A exists 
as an equilibrium mixture of the bicyclic and monocyclic forms. Introducing two fluorine atoms 
at the α-position of the keto group effectively locks the compound in the bicyclic form. Comparing 
the activity of ripostatin A and its difluorinated analogue revealed that the bicyclic-trapped 
analogue difluororipostatin A is two orders of magnitudes less active than ripostatin A, suggesting 
that the monocyclic form of ripostatin A is the active form.46 
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Scheme 1.4. Fluorinated analogue of ripostatin A 
 
1.2.2. Stereoselective Reformatsky 
The Honda modification of the Reformatsky reaction is a mild transition metal-catalyzed 
reaction in which the Wilkinson catalyst RhCl(PPh3)3 is used with Et2Zn as the zinc source.
57 The 
use of Et2Zn ensures the homogeneity of the reaction mixture which facilitates the design of 
stereoselective variations of the reaction. Honda applied these conditions to the synthesis of chiral 
β-amino esters via a three-component coupling, using the (R)-phenylglycinol chiral auxiliary.58 
Fuji and co-workers were the first to use the Reformatsky-Honda reaction in the diastereoselective 
formation of fluorinated substrates. They reported the diastereoselective synthesis of α,α-difluoro-
β-amino ester from ethyl bromodifluoroacetate and chiral aldimine.59  
Several studies used variations of the Reformatsky reaction for the stereoselective synthesis 
of fluoro-β-amino esters, fluoro-β-hydroxy esters and fluoro-β-lactams. In these reactions, 
diastereoselectivity can be achieved by using chiral imines (Scheme 1.5 (a)),60 chiral 
sulfinylimines,61-63 or chiral fluorobromoesters (Scheme 1.5 (b)).64 On the other hand, amino 
alcohol chiral ligands (such as ligand 15) were shown to promote enantioselective Reformatsky 
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reactions with imines65-66 and ketones67 (Scheme 1.5 (c)). Moreover, using ethyl 
dibromofluoroacetate gives access to syn-α-bromo-α-fluoro-β-lactams68 which can further react 
with aryl Grignard reagents69 or aryl-(9-BBN) reagents70 to introduce an aryl group at the α-
position, or with butyl lithium followed by alkyl halides or carbonyl compounds to alkylate the 
same position.71  
 
Scheme 1.5. Stereoselective synthesis of fluoro-β-lactams via Reformatsky reaction 
 
The diastereoselective Reformatsky-Honda reaction has found useful applications in the 
synthesis of fluoroalkene peptidomimetics. These compounds are structurally similar to peptides 
but are resistant to enzymatic action which makes them appealing peptide-based probes. Fujii and 
co-workers disclosed a synthetic methodology for (Z)- and (E)-fluoroalkenes in which they utilized 
Reformatsky-Honda reaction (Scheme 1.6).72 The (Z)- and (E)-fluoroalkenes (1.17 and 1.19) act 
as trans- and cis-amide (1.18 and 1.20) isosteres, respectively. When the affinities of the 
fluoroalkenes were determined for the peptide transporter PEPT1, the (Z)-fluoroalkene shows 
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higher affinity suggesting that this transporter binds to the trans conformation of the peptide.72 A 
similar strategy was applied in the synthesis of fluoroalkene analogues of α-helical anti-HIV 
peptide73 and CXCR4 antagonistic pseudopeptide,74 and the endogenous opioid neuropeptide, 
Leu-enkephalin.75 
 
Scheme 1.6. Reformatsky-Honda reaction in the synthesis of fluoroalkene peptidomimetics 
 
1.3. Copper-mediated Michael Additions 
The copper-mediated Michael addition was first reported by Kumadaki and co-workers. In 
this work, copper powder in DMSO is used to react ethyl α,α-bromodifluoroacetate with Michael 
acceptors (Scheme 1.7 (a)).76 In a following study, Kumadaki reported an improved protocol that 
utilizes the bidentate ligand tetramethylethylenediamine (TMEDA) to promote the reaction using 
THF as a solvent, and this modification resulted in better yields and easier work up.77 Recently, 
Shin and co-workers disclosed that adding a protic additive, namely acetic acid (AcOH), reduced 
the side products and improved the yields.78 In addition, they applied the optimized conditions in 
large-scale preparation of gemigliptin, a dipeptidyl peptidase-IV (DPP-IV) inhibitor (Scheme 1.7 
(b)).78 
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Scheme 1.7. (a) Copper-mediated Michael addition conditions, (b) application in gemigliptin 
synthesis 
 
 
1.3.1. Application of Copper-mediated Michael additions 
Applications of the copper-mediated Michael addition include the construction of 
heterocycles as building block in medicinal chemistry. Examples of these applications include the 
reaction of ethyl α,α-bromodifluoroacetate with acrylonitrile to give rise to ethyl 4-cyano-2,2-
difluorobutanoate, which then can cyclize to form difluoropiperidines or difluoroglutaric 
anhydride (Scheme 1.8).79-81 This method provides access to novel building blocks via simple 
protocols and readily available starting materials. 
 
Scheme 1.8. Copper-mediated Michael addition application in the synthesis of heterocycles 
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Jiracek and co-workers applied the copper-mediated Michael addition in the synthesis of a 
trifunctional scaffold that can be selectively functionalized for biological applications like 
sequential bioconjugations.82 In this synthesis, the Michael addition reaction was used to install a 
difluorinated spacer (Scheme 1.9), which allowed the use of 19F NMR to quantify the fluorine-
containing compounds in the crude mixture at the end of the solid-phase synthesis. 19F NMR can 
later be used to quantify the products of any following application of this scaffold.   
 
Scheme 1.9. Fluorinated trifunctional scaffold 
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1.4. Copper-promoted Coupling to Vinyl and Aryl Halides 
Kobayashi and co-workers reported the copper-promoted coupling of iododifluoroacetate 
to vinyl and aryl halides, in which three equivalents of iododifluoroacetate reacted with one 
equivalent of the alkenyl halide in DMSO.83 In a following publication, Kobayashi further 
investigated the effects of solvent on the coupling reaction using 19F NMR. He found that HMPA 
better stabilized the reaction intermediate, produced less by-products and resulted in almost 
quantitative conversion.84 However, Kobayashi’s attempts to apply this method to 
bromodifluoroacetate were unsuccessful. Over a decade later, Kumadaki and co-workers expanded 
this method to the cheaper bromodifluoroacetate by using activated copper in DMSO and reducing 
the number of bromodifluoroacetate equivalents to one equivalent. This helped reduce the 
formation of the double addition by-product.85 The Kumadaki modification was incompatible with 
alkyl and alkynyl halides,85 on the other hand, the Kobayashi method resulted in poor in DMSO83 
and moderate to good in HMPA.84 Kumadaki and Kobayashi proposed different complexes as the 
active intermediate in this reaction, presumably the choice of solvent determines which 
intermediate is formed (Scheme 1.10). α-Silyldifluoroacetates have also been shown to participate 
in this reaction. In a report from Amii and co-workers, copper iodide and potassium fluoride were 
heated in DMF to promote the coupling of silyldifluoroacetates with aryl halides.86 Furthermore, 
this reaction is not limited to fluoroacetates; fluoroamides, fluorosulfones and even fluoromethyl-
benzo-1,3-oxazoles which have been shown to participate in a cross-coupling reaction.87  
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Scheme 1.10. Copper-promoted coupling to vinyl and aryl halides 
 
Hu and co-workers investigated the selectivity of the copper-mediated coupling  reaction 
and found that in the presence of a coupling partner, the cross-coupling adduct is the major product 
(Scheme 1.11 (a)); however, in the absence of a suitable coupling partner, the homocoupling 
product was predominantly formed especially when one of the nitrogen substituents is a hydrogen 
atom.88 For cases in which one of the substitutions on the nitrogen is an aromatic ring, a competing 
intramolecular cyclization takes place, especially with electron rich rings (Scheme 1.11 (b)).  
 
Scheme 1.11. Selectivity of copper-mediated reactions 
 
1.4.1. Applications of Copper-promoted Coupling to Vinyl and Aryl Halides 
The product of this copper-mediated coupling reaction is different from most other 
difluoromethylation methods in that it doesn’t contain an α-hydroxy group, because this group is 
relatively difficult to remove. Thus, this cross-coupling reaction has enabled new developments in 
synthetic methodologies by providing novel fluorinated starting materials.89-92 Silver-catalyzed 
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decarboxylative difluoromethylenation is enabled by a copper-mediated coupling followed by 
hydrolysis and decarboxylation of 2,2-difluoro-2-phenylacetic acid using Ag(I) (Scheme 1.12). 
The intermediate is a radical that can be alkenylated using ethynyl-benziodoxolone reagents,93 18F 
labelled,94-95 or can add to isocyanide followed by intramolecular cyclization to form 
difluoromethylenated phenanthridine.96 
 
Scheme 1.12. Silver-catalyzed decarboxylative difluoromethylenation 
This coupling reaction has found applications in the synthesis of biologically active 
compounds.97-99 For instance, Wilson and co-workers utilized it in their search of an efficient 
scalable protocol for the synthesis of a thrombin inhibitor.100 In the optimization of the synthesis 
of a difluoroethylester intermediate, the original route used NFSI at –78 °C to fluorinate the 
starting material (Scheme 1.13). To avoid running the reaction at low temperature, a second route 
was developed in which Deoxo-Fluor was used to introduce the two fluorines. Nonetheless, both 
routes used expensive fluorinating reagents and were relatively low yielding. Hence, they explored 
a third route that employed the copper-mediated coupling reaction to incorporate the fluorine 
atoms using the bromodifluoroacetate building block which proceeded in very good yield.   
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Scheme 1.13. Optimizing the synthesis of a thrombin inhibitor 
1.5. Decarboxylative Reactions 
Decarboxylative reactions can be used to assemble fluorinated compounds. Starting with 
α,α-difluoro-β-keto acids or esters, heat with or without the help of a metal catalysts is employed 
to release CO2 and form difluoroenolates. Although this method forms fluoroenolates under neutral 
conditions, it frequently requires the use of high temperatures which might limit its applications. 
Decarboxylative aldol reactions generate α,α-difluoro-β-hydroxyketones when heated to 100 
°C,101 or when catalyzed by copper-phenanthroline complex in addition to heating to 80 °C 
(Scheme 1.14 (a) & (b)).102 Also, palladium-catalyzed decarboxylative benzylation reactions can 
be used to form α-benzyl-α,α-difluoroketones when heated to 120 °C (Scheme 1.14 (c)).103 
Similarly, α-allyl-α,α-difluoroketones can be accessed using palladium-catalyzed decarboxylative 
allylation reactions product (Scheme 1.14 (d)). In this allylation reaction, the regioselectivity of 
the addition is dependent on the ligand. Specifically, when t-BuBrettPhos is used the linear product 
is predominantly formed, whereas when PhXPhos is used the branched form is the main product.104 
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Scheme 1.14. Decarboxylative reactions in the synthesis of difluorinated compounds 
1.6. Trifluoroacetate-release Reactions 
The trifluoroacetate-release method is an innovative technique that generates 
fluoroenolates from highly fluorinated β-keto-gem-diols via C-C bond scission under mild 
conditions.105 In the presence of a metal salt, mild bases such as triethylamine and potassium 
bicarbonate are added to cleave the C-C bond, form fluoroenolates, and release trifluoroacetate 
over the course of a few minutes (Scheme 15 part (a)). Stronger bases such as NaH, KHMDS and 
n-BuLi can be used as well, and under these conditions, the reaction is usually instantaneous.  Salts 
of metals including lithium, copper, zinc and magnesium are typically added to the reaction 
mixture to accelerate the reaction and stabilize the fluoroenolates.106  
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1.6.1. Applications of Trifluoroacetate-release Reactions 
The fluoroenolates produced via the trifluoroacetate-release approach have been shown to 
react with various electrophiles (Scheme 1.15 (a)). The trifluoroacetate-release based aldol 
reaction with aldehydes was the first reported reaction to utilize this approach. The reaction 
produced α,α-difluoro-β-hydroxy ketones in good to excellent yields and with a wide substrate 
scope, including aromatic and aliphatic aldehydes.105 Attempts to extend the scope of this reaction 
to ketones were limited to the highly activated trifluoromethyl aryl and heteroaryl ketones which 
requires the use of a strong base, namely LiHMDS, to effect the transformation in good yields.107 
Trifluoroacetate-release Mannich reactions have been reported with activated imines such as N-
sulfinyl,108 N-sulfonyl,109-110 N-Boc,109 and N-tosyl imines.110 This method was later extended to 
non-activated imines by utilizing magnesium salts. The trifluoroacetate-release Mannich reaction 
was applied in the synthesis of difluoromethyl tetrahydroisoquinolines through the reaction of 
difluoroenolates with dihydroisoquinolines that are generated in situ by visible-light photoredox 
catalysis.111  
The difluoroenolates can also be trapped with water or deuterated water to produce 
difluoromethyl ketones112 and deutero-methyl ketones respectively.113 Furthermore, 
difluoroenolates generated from pentafluoro-gem-diols react with halogenation reagents including 
I2, Br2, and NCS to generate iodo, bromo and chlorodifluoromethyl ketones. In a similar manner, 
2-chloro-2,4,4,4-tetrafluoro-gem-diols can undergo trifluoroacetate-release followed by 
bromination to produce bromochlorofluoromethyl ketones respectively.114 The 
iododifluoromethyl ketones formed using the trifluoroacetate-release halogenation reaction were 
further utilized in methodologies to access α,α-difluoro-β,γ-alkenyl ketones115 and α,α-
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difluorobenzoyl oxygen heterocycles.116 An interesting application of the trifluoroacetate-release 
reaction is the synthesis of CF2Br-glucopyranose 1.33 (Scheme 1.15 (b)). Starting with 
pentafluoro-gem-diol 1.32, a tandem cascade reaction ensued upon the addition of triethylamine. 
A series of  trifluoroacetate-release, halogenation, deprotection, and finally cyclization produced 
1.33 as a single diastereomer in 41% yield.117 
 
Scheme 1.15. Reactions of fluoroenolates generated via trifluoroacetate release 
1.6.2. Synthesis of Highly Fluorinated gem-diols 
Typically, highly fluorinated gem-diols are synthesized from ketones through 
trifluoroacetylation using trifluoroethyl trifluoroacetate118 followed by fluorination using 
Selectfluor (Scheme 1.16 (a)).105 This method can be applied to ketones with two α-protons to 
generate pentafluoro-gem-diols105 and to ketones with one α-proton to form tetrafluoro-gem-
diols.119 The fluorination step can be modified to produce tetrafluoro-gem-diols from ketones with 
two α-protons by limiting the number of Selectfluor equivalents to one. However, this approach 
results in modest yields and is complicated by the formation of the difluorinated by-product.120 To 
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improve the efficiency of this transformation, Wu and co-workers reported using copper nitrate as 
a catalyst and a water/acetonitrile mixture as the reaction solvent to get tetrafluoro-gem-diols in 
high yields.121 Alternatively, highly fluorinated gem-diols can be accessed from aldehydes through 
the addition of fluoroenolates generated from hexafluoroisopropanol followed by oxidation of the 
β-hydroxy group to a β-keto group (Scheme 1.16 (b)). In this technique, lithium 
pentafluoropropen-2-olate can be formed by treating hexafluoroisopropanol with n-BuLi.117, 122-123 
however, a milder alternative employs magnesium pentafluoropropen-2-olate generated from (i-
Pr)2NMgCl·LiCl and hexafluoroisopropanol.
124 
 
 
Scheme 1.16. Synthesis of highly fluorinated gem-diols 
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1.6.3. Stereoselective Trifluoroacetate-Release Reactions 
The use of difluoroenolates in asymmetric reactions can be challenging. Even though the 
stereoselective Reformatsky reaction has found some success, it usually requires the use of 
stoichiometric amounts of chiral ligands to accomplish these transformations. On the other hand, 
the mild homogeneous conditions of the trifluoroacetate-release reaction lend themselves well to 
stereoselective control. Consequently, an array of catalytic reactions with various substrates have 
been reported to utilize this method for the assembly of stereogenic centers. These reactions 
employ different types of ligands, including bis(oxazoline) (BOX), thiourea, diamine and 
monophosphine ligands. Zhang and Wolf reported a catalytic enantioselective trifluoroacetate-
release aldol reaction, in which α,α-difluoro-β-hydroxy ketones are synthesized using copper(II) 
triflate (5 mol%) and the new chiral bidentate BOX ligand 1.34 (6 mol%) (Scheme 1.17 (a)).106 
Pan and co-workers utilized a similar method in the catalytic asymmetric synthesis of C-F 
quaternary stereogenic centers using the t-butyl-substituted BOX ligand 1.35, first with aromatic 
aldehydes119 and later with alkyl aldehydes but with less success (Scheme 1.17 (b)).125 In a 
following paper, Pan applied the same reaction in a cascade aldol–cyclization reaction to prepare 
2-fluoro-isobenzofuran-1(3H)-one in good diastereoselectivities and enantioselectivities (Scheme 
1.17 (c)).126 Stereoselective trifluoroacetate-release Mannich reactions have also been developed. 
Cyclic tetrafluoro-gem-diols react with isatin-derived ketimines using the diamine ligand 1.36 
(Scheme 1.17 (d))127 and chiral N-sulfinylimines without the use of chiral ligands (Scheme 1.17 
(e))128 to generate α-fluoro-β-keto-amines in high diastereoselectivities. Furthermore, catalytic 
enantioselective aryl coupling reactions can be accomplished using palladium complex and (S)-
difluorphos or (S)-segphos ligands.129 
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Scheme 1.17. Stereoselective trifluoroacetate-release reactions to install C-F quaternary 
stereogenic centers 
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Several other methods employ trifluoroacetate-release reactions using thiourea-based 
ligands to introduce the monofluoroalkyl group enantioselectively. Wu and co-workers used ligand 
1.37 to produce 3-hydroxy oxindoles through aldol reactions with indoline-2,3-diones (Scheme 
1.18 (a)).121 In a similar effort, Wang and co-workers asymmetrically synthesized 3-alkyl 
oxindoles by utilizing ligand 1.38 and using 3‑bromooxindoles as indol-2-ones precursors 
(Scheme 1.18 (b)).130 The method was also applied to Micheal addition reactions with nitroolefins 
using the same ligand but with lower stereocontrol (Scheme 1.18 (c)).131  
 
Scheme 1.18. Stereoselective trifluoroacetate-release reactions to install monofluoroalkyl group  
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CHAPTER 2 
DEVELOPMENT OF FLUORINATION METHODOLOGY  
2.1. Difluoromethyl Ketones 
The development of fluorination methods to install the difluoromethyl (CF2) group is of 
particular interest to medicinal chemists. The CF2H group can act as a hydrogen bond donor, 
whereas the fluorine lone pair can partake in hydrogen bonding as an acceptor.132 Moreover, the 
CF2 group is considered a valuable bioisostere of oxygen since it has comparable size and 
electronic properties to oxygen, and can coordinate different metals such as Na+, K+, Mg2+, and 
Ca2+.133 We are principally interested in the α,α-difluoromethyl keto group. This group has great 
potential as a synthetic intermediate as well as having prospective pharmaceutical applications. 
Difluoromethyl ketones have been used in enzyme and receptor modulators, like serine134 and 
aspartyl protease inhibitors135 (Figure 2.1). 
 
 
Figure 2.1. Serine and aspartyl protease inhibitors containing difluoromethyl keto group 
 
The high electronegativity of the neighboring fluorine atoms activates the keto group to 
nucleophilic attacks. Also, this group exists as a mixture of the keto and diol (hydrated) forms, in
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the presence of water (Figure 2.2a). The diol improves the water solubility of the compound, and 
in the context of enzyme binding, the tetrahedral shape of the hydrated form mimics a tetrahedral 
transition state which might result in favorable binding. Furthermore, in some structures, the 
increased electrophilicity of the fluorinated keto group facilitates intramolecular attacks that can 
lead to the formation of the corresponding hemiacetal. An example of this transformation can be 
seen in Lubiprostone, which exists as a mixture of the keto and hemiacetal forms (Figure 2.2b).136 
The bicyclic hemiacetal is the active form of this drug.  
 
 
Figure 2.2. a) Keto and diol forms of difluoromethyl keto group, b) ketone and hemiacetal forms 
of Lubiprostone 
 
 
2.2. Preparation of Difluoromethyl Ketones 
Current methods to access difluoromethyl ketones include magnesium catalyzed 
defluorination of trifluoromethyl ketones,137 alkylation of ethyl difluoroacetate utilizing Grignard 
reagents138 and difluoromethylation of acyl chlorides using N-heterocyclic carbene Ag(CF2H) 
complexes.139 These methods typically require the use of sensitive organometalics and can be low 
yielding. We aim to utilize the trifluoroacetate-release method to generate difluoromethyl ketones.  
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When difluoroenolates are generated in the absence of an electrophile and then quenched 
with water, the difluoromethyl ketone product can be observed only in about a 5% yield, because 
the self-adduct is the major product (Scheme 2.1a). To prevent the formation of the self-adduct 
product, we decided to add water to the reaction mixture before the fragmentation process begins 
to trap the enolate as soon as it forms. Fortunately, this procedure produced the difluoromethyl 
ketone as the major product (Scheme 2.1b).113 
 
 
Scheme 2.1. Using water to trap difluoromethyl enolates as difluoromethyl ketones 
 
In this method, the generation of α,α-difluoromethyl ketones can be accomplished under 
mild conditions through a base-mediated fragmentation of pentafluoro-gem-diols in the presence 
of water (Scheme 2.2). This process is compatible with aromatic, heteroaromatic and aliphatic 
ketones. The trifluoroacetate-release method generates difluoromethyl ketones in good yields 
without issues of over- or under-fluorination.113  
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Scheme 2.2. Preparation of difluoromethyl ketones 
 
2.3. Preparation of Deuterated Difluoromethyl Ketones 
The incorporation of deuterium into pharmaceuticals to block sites of metabolism is a 
growing field. The stronger deuterium-carbon bond is harder to break than a hydrogen-carbon 
bond, and this change slows the metabolism of deuterated agents. In 2017, Austedo became the 
first deuterium containing drug to be approved by the FDA. Austedo is the deuterated analogue of 
Xenazine; a drug used for the treatment of chorea associated with Huntington’s disease (Figure 
2.3). The six methoxy protons of Xenazine are replaced by deuterium atoms to produce Austedo, 
doubling the half-life of this drug.140    
 
Figure 2.3. Structures of Austedo and Xenazine 
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We are interested in developing a method to generate deuterated difluoromethyl 
compounds. The two reported CF2D-based reagents are derived from trifluoromethylating reagents 
by replacing one of the fluorines with a deuterium atom (Figure 2.4). Reagent 2.8 derived from 
the Rupert-Prakash reagent has been reported to deliver a deuterium atom rather than a CF2D 
group.141 On the other hand, the sulfoximine-based reagent 2.9 successfully introduces a CF2D 
group, albeit with low deuterium incorporation yields.142 
 
Figure 2.4. Structures of CF2D-based reagents 
The trifluoroacetate-release protocol developed for the synthesis of α,α-difluoromethyl 
ketones can be adopted to generate α-deutero-α,α-difluoromethyl ketones by substituting D2O for 
water. This process produced α-deutero-α,α-difluoromethyl ketones in very good yields. 
Fortunately, the deuterated ketones were generated with excellent levels of deuterium 
incorporation (>97%) (Scheme 2.3).113  
 
Scheme 2.3. Preparation of deutero difluoromethyl ketones 
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Over-deuteration at susceptible α-positions is observed in the presence of D2O and base, 
such as in compounds 2.11 and 2.12 (Scheme 2.3). Fluorine substituents noticeably reduce the 
acidity of neighboring deuteriums; thus, the formation of CF2 carbanion by dedeuteration of CF2D 
is a slow unfavorable process. Therefore, over-deuteration can easily be addressed utilizing the 
differences in acidity between the deuterium atoms on the two α-carbons. Treating the over-
deuterated product 2.11 with triethylamine in water replaces the deuterium atoms on the non-
fluorinated α-carbon with hydrogen, whereas the deuterium on the fluorinated carbon atom is 
stable under these conditions and no exchange is observed (Scheme 2.4). 
 
Scheme 2.4. Selective dedeuteration on the non-fluorinated α-position 
 
2.4. Preparation of Monofluoromethyl Ketones 
Typically treating trifluoromethyl β-diketones with Selectfluor in acetonitrile results in 
difluorination of the α-carbon. Wu and co-workers reported that monofluorination of these 
diketones can be accomplished in presence of cupper nitrate as a catalyst (Scheme 2.5a).121 We 
have found that carrying the reaction in acetonitrile and water in absence of a catalyst produced 
the monofluoronated product in high yields (Scheme 2.5b).  
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Scheme 2.5. Monofluorination of trifluoromethyl β-diketones 
 
The monofluoronation of trifluoromethyl β-diketones under these conditions produced the 
tertafluorinated gem-diol products in very good yields for aromatic and aliphatic substrates 
(Scheme 2.6a).  The tertafluorinated gem-diol product can go through trifluoroacetate release to 
generate a monofluoromethyl enolate. These enolates can be quenched with water to generate 
monofluoromethyl ketones in good yields (Scheme 2.6b). 
 
Scheme 2.6. Preparation of monofluoromethyl ketones 
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2.5. Preparation of Fluoromethyl Sulfones 
Difluoromethyl sulfones are useful difluoromethylating reagents. They can be used to 
install a CF2H moiety by deprotonation of the difluoromethyl group to generate a difluoromethyl 
sulfone carbanion that attacks an electrophile to add a difluoromethyl sulfone group, followed by 
desulfonation and protonation. This process has been shown to generate alkylated 
difluoromethylene by substituting a halide atom (Scheme 2.7a),143 and α-difluoromethyl alcohols 
in reactions with carbonyl (Scheme 2.7b).144  
 
Scheme 2.7. Difluoromethyl sulfones use as difluoromethylating reagents 
Difluoromethyl sulfones are usually synthesized from thiols using dangerous gases like 
chlorodifluoromethane and dibromodifluoromethane. We aim to develop a method to prepare 
fluorinated sulfones that avoids these gases. Typically, the starting material of the trifluoroacetate 
release process is α-keto pentafluoro gem-diol. The keto group stabilizes the carbanion that forms 
upon fragmentation. We envisioned that α-sulfonyl pentafluoro gem-diols would be capable of 
effecting the same fragmentation as its ketone counterpart. The synthesis of α-sulfonyl pentafluoro 
gem-diols starts with methyl sulfones that can be trifluoroacetylated using trifluoroethyl 
trifluoroacetate which would then be fluorinated using Selectfluor (Scheme 2.8a). Trifluoroacetate 
release from sulfonyl pentafluoro-gem-diols followed by protonation will generate difluoromethyl 
and monofluoromethyl sulfones, respectively (Scheme 2.8b).113     
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Scheme 2.8. Preparation of difluoromethyl sulfones 
 
The temperature at which the fluorination reaction is carried out controls the level of 
fluorination; monofluorination is predominant at room temperature and heating at reflux is needed 
to push the reaction toward difluorination. We exploited this selectivity to prepare tetrafluoro gem-
diols from methyl ketones at room temperature (Scheme 2.9a). With tetrafluoro gem-diols on 
hand, monofluorinated methyl ketones can be accessed using the trifluoroacetate release process 
(Scheme 2.9b). 
34 
 
 
Scheme 2.9. Preparation of monofluoromethyl sulfones 
 
 
2.6. Preparation of Deuterated Fluoromethyl Sulfones 
Extending this method to synthesize α-deutero-α,α-difluoromethyl sulfones proved easy. 
The substitution of H2O with D2O provided the deuterated analogues in good yields and with 
deuterium incorporation yields ≥ 96% (Scheme 2.10). This represents a simple method for the 
synthesis of novel deuterodifluoromethylating reagents that were not reviously reported. The 
process was less efficient in generating the α,α-dideutero-α-fluoromethyl sulfone 2.50. In the case 
of this compound, a mixture of the CFH2, CFHD, and CFD2 analogues was retrieved with desired 
product 2.50 constituting 91% of this mixture.113  
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Scheme 2.10. Preparation of deuterofluoromethyl sulfones 
 
2.7 Experimental Details 
All reactions were performed in oven-dried glassware. All air and moisture sensitive 
solvents were transferred via syringe. Column chromatography was performed using Sorbent 
Technologies silica gel (200–400 mesh). 
Representative Reaction Procedure for Preparation of α,α-Difluoromethyl Ketones. A 
solution of 1-(benzothiophen-3-yl)-2,2,4,4,4-pentafluoro-3,3-dihydroxybutan-1-one145 (25 mg, 
0.08 mmol) in H2O/THF (2 mL/0.5 mL) was treated with Et3N (21 µL, 0.15 mmol), and the 
resultant mixture was stirred for 10 min at rt. The organics were extracted with CH2Cl2 (3 × 5 mL), 
dried over Na2SO4, and concentrated under reduced pressure. SiO2 flash chromatography (17:3 
hexanes/Et2O) afforded the title compound 2.4 as a colorless oil (15 mg) in 93% yield. 
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1-(Benzothiophen-3-yl)-2,2-difluoroethanone 2.4. See representative reaction procedure: 1H 
NMR (500 MHz, CDCl3) δ 8.78–8.73 (m, 1H), 8.70 (t, J = 1.5 Hz, 1H), 7.95–7.89 (m, 1H), 7.55 
(ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 7.52–7.45 (m, 1H), 6.22 (t, J = 53.8 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 182.4 (t, J = 25.4 Hz, 1C), 141.3 (t, J = 6.1 Hz, 1C), 139.0, 136.6, 128.6, 126.4, 126.0, 
125.1, 122.2, 111.5 (t, J = 254.7 Hz, 1C);19F NMR (282 MHz, CDCl3) δ –121.1 (d, JHF = 53.8 Hz, 
2F); IR(film) νmax 1679, 1491, 1462, 1424, 1135, 1109, 1055 cm–1; HRMS (CI) m/z calcd for 
C10H6F2OS (M)
+ 212.0107, found 212.0109. 
 
1,1-Difluoro-4-phenylbutan-2-one 2.5. See representative reaction procedure. 4,4,6,6,6-
Pentafluoro-5,5-dihydroxy-1-phenylhexan-3-one145 (35.7 mg, 0.120 mmol), Et3N (67 μL, 0.48 
mmol), and H2O/THF (1.5 mL/1.5 mL) were used. The title compound 2.5 was isolated as a 
colorless oil in 99% yield (22 mg). All spectral and characterization data matched the reported 
data.146 
 
 
1,1-Difluorooctan-2-one 2.6. See representative reaction procedure. 1,1,1,3,3-Pentafluoro-2,2-
dihydroxydecan-4-one (44.8 mg, 0.161 mmol), Et3N (91 μL, 0.64 mmol), and H2O/THF (1.6 
mL/1.5 mL) were used. The title compound 2.6 was isolated as a colorless oil in 88% yield (23 
mg). All spectral and characterization data matched the reported data.146 
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3-(tert-Butyldimethylsilyl)-21-(trifluoroacetyl)pregnenolone. To –78 °C solution of n-BuLi 
(120 µL, 1.56M in hexanes) in THF (6 mL) was added hexamethyldisilazane (303 mg, 1.88 mmol) 
dropwise. The mixture was stirred at –78 °C for 20 min, and then, 3-(tert-
butyldimethylsilyl)pregnenolone147 (678 mg, 1.57 mmol) was added. The resultant mixture was 
stirred for 45 min at –78 °C. Next, 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (461 mg, 2.35 mmol) 
was added dropwise and the mixture was stirred for 15 min at –78 °C. The reaction mixture was 
quenched with 1 M aq. H2SO4 (10 mL) and stirred for 10 min. The resultant mixture was extracted 
with CH2Cl2 (10 mL × 3), and the organics were dried over Na2SO4. Concentration under reduced 
pressure afforded the title compound in 74% yield (610 mg) as a solid: mp 96–98 °C; 1H NMR 
(500 MHz, CDCl3) δ5.86 (s, 1H), 3.54 (tt, J = 10.8, 4.7 Hz, 1H), 2.43 (t, J = 9.0 Hz, 1H), 2.18 – 
2.07 (m, 1H), 1.89 (dd, J = 8.2, 2.6 Hz, 1H), 1.82–1.72 (m, 2H), 1.71–1.63 (m, 3H), 1.62–1.56 (m, 
1H), 1.49–1.41 (m, 2H), 1.38 (dt, J = 18.3, 4.9 Hz, 1H), 1.35–1.29 (m, 1H), 1.30–1.22 (m, 6H), 
1.20–1.13 (m, 1H), 1.07 (dtd, J = 12.7, 8.0, 3.1 Hz, 1H), 0.98–0.91 (m, 3H), 0.88 (s, 9H), 0.80 (s, 
3H), 0.65 (s, 3H), 0.05 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 198.6, 174.8 (q, JCF = 36.0 Hz, 1C), 
118.3 (q, JCF = 218.3 Hz, 1C), 96.4, 72.0, 59.3, 56.7, 54.3, 46.5, 45.0, 38.6, 38.5, 37.1, 35.7, 35.6, 
32.1, 31.9, 28.6, 26.0 (3), 24.4, 22.8, 21.1, 18.3, 13.4, 12.4, –4.6 (2); 19F NMR (282 MHz, CDCl3) 
δ −75.8 (s, 3F); IR (film) νmax 2930, 2855, 1593, 1200, 1157, 1107, 1090, 836 cm−1; HRMS (ESI) 
m/z calcd for C29H47F3O3Si (M+Na)
+ 551.3144, found 551.3149; [α]23D +70° (c 1.03, CHCl3). 
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3-(tert-Butyldimethylsilyl)-21,21-difluoro-21-(2,2,2-trifluoro-1,1-dihydroxyethyl)-
pregnenolone. A solution of 3-(tert-butyldimethylsilyl)-21-(trifluoroacetyl)pregnenolone (277 
mg, 0.52 mmol) in CH3CN (2 mL) and THF (2 mL) was treated with Selectfluor (464 mg, 1.31 
mmol). After 24 h, Selectfluor (300 mg, 0.98 mmol) was added and the mixture was stirred for an 
additional 24 h. Next, the reaction was diluted with EtOAc (50 mL) and filtered through Celite. 
The residue was concentrated in vacuo, dissolved in CH2Cl2 (20 mL), and washed with water (20 
mL). The aqueous layer was extracted with CH2Cl2 (20 mL). The combined organics were dried 
over Na2SO4 and concentrated under reduced pressure to give the title compound in 83% yield 
(252 mg) as a solid: mp 108–111 °C;1H NMR (500 MHz, CDCl3) δ 4.67 (s, 2H), 3.54 (tt, J = 10.8, 
4.8 Hz, 1H), 3.17 (t, J = 8.8 Hz, 1H), 2.20–2.09 (m, 1H), 1.93 (d, J = 12.3 Hz, 1H), 1.84–1.71 (m, 
2H), 1.71–1.63 (m, 4H), 1.58 (dt, J = 9.7, 3.1 Hz, 1H), 1.48–1.38 (m, 3H), 1.32 (d, J = 10.8 Hz, 
1H), 1.30–1.20 (m, 6H), 1.11–1.02 (m, 1H), 0.99–0.90 (m, 3H), 0.88 (s, 9H), 0.79 (s, 3H), 0.69 (s, 
3H), 0.05 (s, 6H);13C NMR (125 MHz, CDCl3) δ 207.0 (t, JCF = 28.6 Hz, 1C), 121.9 (q, JCF = 283.3 
Hz, 1C), 108.5 (t, JCF = 265.9 Hz, 1C), 93.0 (qt, JCF = 29.8, 1.0 Hz, 1C), 72.1, 57.3 (2), 54.0, 48.3, 
44.9, 38.5, 38.3, 37.1, 35.8, 35.5, 32.1, 31.8, 28.6 (3), 25.9, 24.6, 24.4, 21.2, 18.3, 13.7, 12.3, –4.6 
(2); 19F NMR (282 MHz, CDCl3) δ −80.8 (t, JFF = 10.4 Hz, 3F), −119.1 (dq, JFF = 35.0, 9.9 Hz, 
2F); IR (film) νmax 3436, 2931, 2858, 1717, 1386, 1209, 1087, 837, 775 cm−1; HRMS (ESI) m/z 
calcd for C29H47F5O4Si (M-H-H2O)
+ 563.2980, found 563.2973; [α]26D +83° (c 2.08, CHCl3). 
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3-(tert-Butyldimethylsilyl)-21,21-difluoropregnenolone 2.7. See representative reaction 
procedure.3-(tert-Butyldimethylsilyl)-21,21-difluoro-21-(2,2,2-trifluoro-1,1-dihydroxyethyl)-
pregnenolone (30 mg, 0.05 mmol), Et3N (29μL, 0.21 mmol), H2O/THF (500 μL/100 μL) were 
used. The reaction mixture was stirred for 1 h at rt. The title compound 2.7 was isolated as a solid 
in 94% yield (23 mg): mp 116–118 °C; 1H NMR (500 MHz, CDCl3) δ 5.63 (t, J = 54.2 Hz, 1H), 
3.55 (ddd, J = 15.7, 10.8, 4.8 Hz, 1H), 2.94 (t, J = 8.9 Hz, 1H), 2.17 (m, 1H), 1.88 (d, J = 12.7 Hz, 
1H), 1.80–1.63 (m, 5H), 1.62–1.56 (dq, J = 13.6, 3.9 Hz, 1H), 1.49–1.17 (m, 11H), 1.13–1.02 (m, 
1H), 0.99–0.90 (ddd, J = 15.9, 8.2, 4.2 Hz, 2H), 0.88 (s, 9H), 0.79 (s, 3H), 0.67 (s, 3H), 0.05 (s, 
6H); 13C NMR (125 MHz, CDCl3) δ 201.3 (t, JCF = 24.9 Hz, 1C), 109.9 (t, JCF = 251.3 Hz, 1C), 
72.1, 57.0, 56.9, 54.2, 46.4, 45.0, 38.6 (3), 37.2, 35.7, 35.5, 32.1, 31.9, 28.6, 26.0, 24.6, 23.6, 21.2, 
18.3, 13.9, 12.3, –4.6 (2); 19F NMR (282 MHz, CDCl3) δ −128.4 (d, JHF = 54.1 Hz, 2F); IR (film) 
νmax 2931, 1732, 1252, 1091 cm−1; HRMS (EI) m/z calcd for C26H43F2O2Si (M-CH3)+ 453.3000, 
found 453.2994; [α]23D +77° (c 0.16, CHCl3). 
Representative Reaction Procedure for Preparation of α-Deutro-α,α-difluoromethyl 
Ketones. A solution of 1-(Benzothiophen-3-yl)-2,2,4,4,4-pentafluoro-3,3-dihydroxybutan-1-
one145 (10 mg, 0.03 mmol) in D2O/THF (2 mL/0.5 mL) was treated with Et3N (9 µL, 0.06 mmol), 
and the resultant mixture was stirred for 10 min at rt. The organics were extracted with CH2Cl2 (3 
× 5 mL), dried over Na2SO4, and concentrated under reduced pressure. SiO2 flash chromatography 
(17:3 hexanes/Et2O) afforded the title compound 2.10 as a colorless oil (5.7 mg) in 86% yield 
(97% deuterium incorporation). 
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1-(Benzo[b]thiophen-3-yl)-2-deutero-2,2-difluoroethanone 2.10. See representative reaction 
procedure: 1H NMR (400 MHz, CDCl3) δ 8.74 (d, J = 8.1 Hz, 1H), 8.69 (s, 1H), 7.91 (d, J = 8.0 
Hz, 1H), 7.55 (t, J = 7.7 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 182.43 
(t, J = 25.6 Hz, 1C), 141.42 (t, J = 6.1 Hz, 1C), 139.0, 136.6, 128.5, 126.4, 126.0, 125.1, 122.2, 
111.2 (tt, J = 252.5, 28.8 Hz, 1C); 19F NMR (376 MHz, CDCl3) δ –121.72 (t, J = 8.1 Hz, 2F); 
IR(film)νmax 3110, 1678, 1490, 1462, 1424, 1375, 1245, 1106 cm–1;HRMS (EI) m/z calcd for 
C10H5DF2OS (M)
+ 213.0170, found 213.0162. 
 
1,1-Difluoro-1,3,3-trideutero-4-phenylbutan-2-one 2.11. See representative reaction procedure. 
4,4,6,6,6-Pentafluoro-5,5-dihydroxy-1-phenylhexan-3-one (57.0 mg, 0.191 mmol), Et3N (107 μL, 
0.765 mmol), and D2O/THF (1.9 mL/1.9 mL) were used. The title compound 2.11 was isolated as 
a colorless oil (30 mg) in 80% yield (98% deuterium incorporation):1H NMR (500 MHz, CDCl3) 
δ 7.32–7.20 (m, 5H), 2.96 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 199.0 (t, J = 26.5 Hz, 1C), 139.8, 
128.6, 128.3, 126.5, 109.5 (tt, J = 251.7, 29.0 Hz, 1C), 37.0 (m, 1C) 28.2; 19F NMR (282 MHz, 
CDCl3) δ –129.3 (t, J = 8.5 Hz, 2F); IR (film) νmax 3066, 3031, 2930, 2870, 2918, 1747, 1605, 
1498, 1456, 1163, 1110, 955 cm–1; HRMS (EI) m/z calcd for C10H7D3F2O (M)
+ 187.0888, found 
187.0868. 
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1-Deutero-1,1-difluoro-4-phenylbutan-2-one 2.14. To a solution of 1,1-difluoro-1,3,3-
trideutero-4-phenylbutan-2-one (10.1 mg, 0.054 mmol) in H2O/THF (0.5 mL/0.5 mL) was added 
Et3N (20 μL, 0.22 mmol) dropwise. After 24h, the reaction was extracted with CH2Cl2 (3 mL × 2). 
The organics were dried over Na2SO4 and concentrated under reduced pressure. The title 
compound 2.14 was isolated as a colorless oil (7.9 mg) in 79% yield: 1H NMR (300 MHz, CDCl3) 
δ 7.03–6.91 (m, 5H), 2.73–2.64 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 198.9 (t, J = 26.5 Hz), 
139.8, 128.6, 128.3, 126.5, 109. 5 (t, J = 28.8 Hz, 1C), 37.7, 28.3; 19F NMR (282 MHz, CDCl3) δ 
–101.06 (t, J = 8.5 Hz, 2F); IR (film) νmax 3065, 3030, 2958, 2918, 2950, 1742, 1660, 1605, 956 
cm–1; HRMS (ESI) m/z calcd for C10H8DF2O (M–H) – 184.0690, found 184.0690. 
 
1-Deutero-1,1-difluoro-3,3-deutero-octan-2-one 2.12. 1,1,1,3,3-Pentafluoro-2,2-
dihydroxydecan-4-one (59.2 mg, 0.213 mmol), Et3N (120 μL, 0.85 mmol), and D2O/THF (2.0 
mL/0.6 mL) were used. The reaction mixture was stirred for 18 h at rt. The title compound 2.12 
was isolated as a colorless oil (29 mg) in 83% yield (98% deuterium incorporation): 1H NMR (300 
MHz, CDCl3) δ 1.60 (m, 2H), 1.36 (m, 6H), 0.95 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 200.2 (dt, J = 26.1, 7.7 Hz, 1C), 110.0 (m, 1C), 35.2, 31.4, 28.5, 22.4, 22.2, 14.0; 19F NMR (282 
MHz, CDCl3) δ –129.24 (t, J = 11.3 Hz, 2F); IR (film) νmax 2955, 2924, 1713, 1464, 1097, 805 
cm–1; HRMS (CI) m/z calcd for C8H11D3F2O (M+H)
+ 168.1279, found 168.1286. 
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3-(tert-Butyldimethylsilyl)-21-deutero-21,21-difluoropregnenolone 2.13. See representative 
reaction procedure. 3-(tert-Butyldimethylsilyl)-21,21-difluoro-21-(2,2,2-trifluoro-1,1-
dihydroxyethyl)-pregnenolone (30 mg, 0.05 mmol) and Et3N (58 μL, 0.41 mmol) were used. The 
reaction mixture was stirred for 12 h at rt. The title compound 2.13 was isolated as a colorless solid 
(20 mg) in 81% yield (99% deuterium incorporation): mp 130–131 °C; 1H NMR (500 MHz, 
CDCl3) δ 3.54 (ddd, J = 15.7, 10.8, 4.8 Hz, 1H), 2.95 (t, J = 8.9 Hz, 1H), 2.15 (m, 1H), 1.91–1.84 
(m, 1H), 1.80–1.63 (m, 5H), 1.61–1.55 (m, 1H), 1.48–1.17 (m, 11H), 1.11–1.02 (m, 1H), 0.98–
0.89 (m, 2H), 0.88 (s, 9H), 0.79 (s, 3H), 0.66 (s, 3H), 0.04 (s, 6H);13C NMR (125 MHz, CDCl3) δ 
201.3 (dt, J = 24.8, 9.5 Hz, 1C), 109.5 (tt, J = 250.9, 28.9 Hz, 1C), 72.0, 57.0, 54.1, 46.4 (2), 44.9, 
38.6, 37.1, 35.6, 35.5, 32.1, 31.9, 28.6, 25.9 (3), 24.6, 23.6, 23.5, 21.1, 18.3, 13.9, 12.3, -4.6 (2); 
19F NMR (282 MHz, CDCl3) δ −129.0–129.1 (m, 2F); IR (film) νmax 2931, 1730, 1252 cm−1; 
HRMS (ESI) m/z calcd for C28H45DF2O2Si (M+H) 470.3371, found 470.3372; [α]D25 +59° (c 0.18, 
CHCl3). 
Representative Reaction Procedure for Preparation of Fluorinated gem-Diols. A solution of 
4,4,4-trifluoro-1-(naphthalen-2-yl)butane-1,3-dione  (200 mg, 0.751 mmol) in CH3CN (2 mL) and 
H2O (2 mL) was treated with Selectfluor® (266 mg, 0.751 mmol) at rt. After 18 h, the reaction 
was diluted with CH2Cl2 (10 ml) and washed with water (10 ml). The aqueous layer was extracted 
with CH2Cl2 (3 × 10 ml). The combined organics were dried over Na2SO4 and concentrated under 
reduced pressure to give the product 2.18 (204 mg) as a solid in 90% yield. 
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2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one 2.18. See representative 
reaction procedure. 1H NMR (400 MHz, CDCl3) δ 8.63 (s, 1H), 8.06–8.02 (m, 2H), 7.96–7.88 (m, 
2H), 7.69 (t, J = 6.9 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 5.89 (d, J = 47.8 Hz, 1H), 5.05 (s, 1H), 4.75 
(s, 1H). 
 
 
 
1-(4-chlorophenyl)-2,4,4,4-tetrafluoro-3,3-dihydroxybutan-1-one 2.19. See representative 
reaction procedure. A solution of 1-(4-chlorophenyl)-4,4,4-trifluorobutane-1,3-dione (60 mg, 0.24 
mmol) in CH3CN (1 mL) and H2O (1 mL) was treated with Selectfluor® (85 mg, 0.24 mmol). The 
title compound 2.19 was isolated as a colorless solid (52 mg) in 76% yield. All spectral and 
characterization data matched the reported data.121 
 
 
 
1-(benzo[d][1,3]dioxol-5-yl)-2,4,4,4-tetrafluoro-3,3-dihydroxybutan-1-one 2.20. See 
representative reaction procedure. A solution of 1-(benzo[d][1,3]dioxol-5-yl)-4,4,4-
trifluorobutane-1,3-dione  (200 mg, 0.769 mmol) in CH3CN (2 mL) and H2O (2 mL) was treated 
with Selectfluor® (273 mg, 0.769 mmol). The title compound 2.20 was isolated as a colorless solid 
(194 mg) in 85% yield. 1H NMR (500 MHz, CDCl3) δ 7.68 (dd, J = 8.2, 2.4 Hz, 1H), 7.46 (d, J = 
1.2 Hz, 2H), 6.90 (d, J = 8.3 Hz, 1H), 6.09 (s, 2H), 5.66 (d, J = 47.8 Hz, 1H), 5.21 (bs, 1H), 4.80 
44 
 
(bs, 1H); 13C NMR (126 MHz, CDCl3) δ 194.0 (d, J = 18.9 Hz), 154.0, 148.6, 129.4, 127.5 (d, J = 
4.9 Hz), 121.8 (q, J = 288.3 Hz), 109.0 (d, J = 3.2 Hz), 108.5, 102.5, 93.1 (dd, J = 35.2, 23.0 Hz), 
85.1 (d, J = 193.6 Hz); 19F NMR (376 MHz, CDCl3) δ –84.7 (d, J = 11.2 Hz, 3F), –195.3 (dq, J = 
47.7, 11.2 Hz, 1F). 
 
 
1-((3r,5r,7r)-adamantan-1-yl)-2,4,4,4-tetrafluoro-3,3-dihydroxybutan-1-one 2.21. To –78 °C 
solution of n-BuLi (600 µL, 2.25 M in hexanes) in THF (6 mL) was added hexamethyldisilazane 
(283 mg, 1.34 mmol) dropwise. The mixture was stirred at –78 °C for 20 min, and then 1-
(adamantan-1-yl)ethan-1-one (200 mg, 1.12 mmol) was added. The resultant mixture was stirred 
for 45 min at –78 °C. Next, 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (226 mg, 1.68 mmol) was 
added dropwise and the mixture was stirred for 15 min at –78 °C. The reaction mixture was 
quenched with 1 M aq. H2SO4 (10 mL) and stirred for 10 min. The resultant mixture was extracted 
with CH2Cl2 (10 mL × 3), and the organics were dried over Na2SO4 and concentrated under 
reduced pressure. The crude mixture was dissolved in CH3CN (2 mL) and H2O (2 mL), then treated 
with Selectfluor® (398 mg, 1.12 mmol). The title compound 2.21 was isolated as a colorless solid 
(348 mg) in 72% yield. 1H NMR (400 MHz, CDCl3) δ 5.39 (s, 1H), 5.26 (d, J = 47.4 Hz, 1H), 4.69 
(d, J = 2.6 Hz, 1H), 2.08 (s, 3H), 1.94–1.83 (m, 6H), 1.74 (q, J = 12.3 Hz, 6H); 13C NMR (126 
MHz, CDCl3) δ 212.4 (d, J = 15.6 Hz, 1C), 121.7 (q, J = 287.1 Hz, 1C), 93.8–92.9 (m, 1C), 82.3 
(d, J = 192.6 Hz, 1C), 47.9 (d, J = 1.1 Hz, 1C), 36.6 (d, J = 1.3 Hz, 3C), 36.3 (3C), 27.5 (3C); 19F 
NMR (377 MHz, CDCl3) δ –85.0 (d, J = 11.0 Hz, 3F), –196.6 (dq, J = 47.6, 11.5 Hz, 1F). 
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Representative Reaction Procedure for Preparation of α,α-Difluoromethyl Ketones. A 
solution of 2,4,4,4-tetrafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)butan-1-one (30 mg, 0.10 mmol) 
in H2O/THF (0.2 mL/0.2 mL) was treated with Et3N (55 µL, 0.40 mmol), and the resultant mixture 
was stirred for 10 min at rt. The organics were extracted with CH2Cl2 (3 × 5 mL), dried over 
Na2SO4, and concentrated under reduced pressure. SiO2 flash chromatography (17:3 
hexanes/Et2O) afforded the title compound 2.22 in 68% yield (12.6 mg). 
 
 
2-fluoro-1-(naphthalen-2-yl)ethan-1-one 2.22. See representative reaction procedure. 1H NMR 
(500 MHz, CDCl3) δ 8.43 (s, 1H), 8.02–7.94 (m, 3H), 7.92 (d, J = 8.1 Hz, 1H), 7.66 (t, J = 7.1 Hz, 
1H), 7.61 (t, J = 7.5 Hz, 1H), 5.68 (d, J = 46.9 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ 193.5 (d, 
JCF = 15.6 Hz), 136.1, 132.5, 131.2, 130.0 (d, JCF = 3.2 Hz), 129.8, 129.2, 129.1, 128.1, 127.3, 
123.4 (d, JCF = 1.9 Hz), 83.8 (d, JCF = 182.7 Hz). 
 
 
1-(4-chlorophenyl)-2-fluoroethan-1-one 2.23. 1-(4-chlorophenyl)-2,4,4,4-tetrafluoro-3,3-
dihydroxybutan-1-one (10 mg, 0.04 mmol), Et3N (24 μL, 0.17 mmol), and H2O/THF (0.1 mL/0.1 
mL) were used. The title compound 2.23 was isolated in 65% yield (4 mg). All spectral and 
characterization data matched the reported data.148 
 
 
1-(benzo[d][1,3]dioxol-5-yl)-2-fluoroethan-1-one 2.24. See representative reaction procedure. 
1-(benzo[d][1,3]dioxol-5-yl)-2,4,4,4-tetrafluoro-3,3-dihydroxybutan-1-one (30 mg, 0.10 mmol), 
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Et3N (57 μL, 0.41 mmol), and H2O/THF (0.2 mL/0.2 mL) were used. The title compound 2.24 was 
isolated in 77% yield (14 mg). 1H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 8.1 Hz, 1H), 7.40 (s, 
1H), 6.87 (d, J = 8.2 Hz, 1H), 6.07 (s, 2H), 5.44 (d, J = 47.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) 
δ 191.6 (d, JCF = 15.5 Hz, 1C), 152.7, 148.6, 128.6, 124.5 (d, JCF = 3.2 Hz, 1C), 108.4, 107.8 (d, 
JCF = 2.8 Hz, 1C), 102.2, 83.6 (d, JCF = 182.3 Hz, 1C); 
 
 
 
1-(adamantan-1-yl)-2-fluoroethan-1-one 2.25. See representative reaction procedure. 1-
(adamantan-1-yl)-2,4,4,4-tetrafluoro-3,3-dihydroxybutan-1-one (30 mg, 0.10 mmol), Et3N (54 μL, 
0.39 mmol), and H2O/THF (0.2 mL/0.2 mL) were used. The title compound 2.25 was isolated in 
74% yield (14 mg). 1H NMR (500 MHz, CDCl3) δ 5.10 (d, J = 47.2 Hz, 2H), 2.04 (s, 3H), 1.84 (s, 
6H), 1.83–1.67 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 208.6 (d, JCF = 12.1 Hz), 208.6, 82.2 (d, 
JCF = 182.9 Hz), 45.2, 37.8, 36.5, 27.7. 
 
 
1,1,1,3,3-pentafluoro-3-(phenylsulfonyl)propane-2,2-diol 2.31. To a –78 °C solution of n-BuLi 
(452 μL, 1.7 M in hexanes) in THF (3 mL) was added hexamethyldisilazane (161 μL, 0.768 mmol). 
After stirring the reaction for 20 min at –78 °C, a solution of methyl phenyl sulfone (100 mg, 0.640 
mmol) in THF (2 ml) was added dropwise. The mixture was stirred for 90 min at –78 °C, and then 
2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (129 μL, 0.960 mmol) was added dropwise. After an 
additional 60 min of stirring at the same temperature the reaction was warmed to room temperature 
and quenched with 1 M H2SO4 (3 mL) and stirred for 60 min. The resultant mixture was extracted 
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with CH2Cl2 (5 mL × 3). The combined organics were dried over Na2SO4 and concentrated under 
reduced pressure. The residue was dissolved in CH3CN (10 mL) and treated with Selectfluor® 
(1.13 g, 3.20 mmol).  After 24 h of stirring at 80 °C, the reaction was diluted with EtOAc (50 ml) 
and filtered through Celite. The filtrate was concentrated under reduced pressure to afford the 
product 2.31 in 87% yield (170 mg) as a colorless solid: mp 84–86 °C; 1H NMR (400 MHz, 
Chloroform-d) δ 8.03 (d, J = 7.8 Hz, 2H), 7.81 (t, J = 7.5 Hz, 1H), 7.65 (t, J = 7.9 Hz, 2H), 5.17 
(bs, 2H); 13C NMR (100 MHz, Chloroform-d) δ 136.6, 132.7, 131.2, 129.9, 121.5 (q, JCF = 289.2 
Hz), 115.0 (t, JCF = 303.3 Hz), 94.2–93.1 (m); 19F NMR (564 MHz, Chloroform-d) δ –82.5 (t, J = 
10.8 Hz, 3F), –111.2 (q, J = 10.8 Hz, 2F); IR (film) νmax 3442, 2925, 2853, 1336, 1177, 1151, 1072 
cm–1; HRMS (ESI) m/z calcd for C9H7ClF5O4S (M+Cl)
– 340.9674, found 340.9645. 
 
 
 
1,1,1,3,3-pentafluoro-3-((4-fluorophenyl)sulfonyl)propane-2,2-diol 2.32. To a –78 °C solution 
of n-BuLi (680 μL, 2 M in hexanes) in THF (5 mL) was added hexamethyldisilazane (288 μL, 
1.38 mmol). After stirring the reaction for 20 min at –78 °C, a solution of 4-fluorophenyl methyl 
sulfone (200 mg, 1.15 mmol) in THF (2 ml) was added dropwise. The mixture was stirred for 90 
min at –78 °C, and then 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (231 μL, 1.72 mmol) was added 
dropwise. After an additional 60 min of stirring at the same temperature the reaction was warmed 
to room temperature and quenched with 1 M H2SO4 (5 mL) and stirred for 60 min. The resultant 
mixture was extracted with CH2Cl2 (10 mL × 3). The combined organics were dried over Na2SO4 
and concentrated under reduced pressure. The residue was dissolved in CH3CN (15 mL) and 
treated with Selectfluor® (2.03 mg, 5.74 mmol).  After 24 h of stirring at 80 °C, the reaction was 
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diluted with EtOAc (50 ml) and filtered through Celite. The filtrate was concentrated under 
reduced pressure to afford the product 2.32 in 82% yield (306 mg) as a colorless solid: mp 74–75 
°C; 1H NMR (400 MHz, Chloroform-d) δ 8.00 (dd, J = 8.7, 4.9 Hz, 2H), 7.25 (appt, J = 8.5 Hz, 
2H), 5.07 (s, 2H).; 13C NMR (100 MHz, Chloroform-d) δ 167.5 (d, JCF = 260.3 Hz), 134.1 (d, JCF 
= 10.3 Hz), 128.5 (d, JCF = 3.1 Hz), 120.9 (q, JCF = 286.8 Hz), 117.0 (t, JCF = 301.0 Hz), 117.1 (d, 
JCF = 23.1 Hz), 94.0 – 92.8 (m); 19F NMR (376 MHz, Chloroform-d) δ –82.5 (t, J = 10.9 Hz, 3F), 
–99.1 (tt, J = 8.2, 5.0 Hz, 1F), –111.0 (q, J = 10.9 Hz, 2F); IR (film) νmax 3445, 3110, 1342, 1177, 
1154, 1075 cm–1; HRMS (EI) m/z calcd for C7H5F3O2S (M+H–TFA)+ 209.9962, found 209.9951. 
 
 
 
1-((2-chlorophenyl)sulfonyl)-1,1,3,3,3-pentafluoropropane-2,2-diol 2.33. To a –78 °C solution 
of n-BuLi (370 μL, 1.7 M in hexanes) in THF (4 mL) was added hexamethyldisilazane (132 μL, 
0.629 mmol). After stirring the reaction for 20 min at –78 °C, a solution of 2-chlorophenyl methyl 
sulfone (100 mg, 0.525 mmol) in THF (1 ml) was added dropwise. The mixture was stirred for 90 
min at –78 °C, and then 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (106 μL, 0.788 mmol) was added 
dropwise. After an additional 60 min of stirring at the same temperature the reaction was warmed 
to room temperature and quenched with 1 M H2SO4 (3 mL) and stirred for 60 min. The resultant 
mixture was extracted with CH2Cl2 (5 mL × 3). The combined organics were dried over Na2SO4 
and concentrated under reduced pressure. The residue was dissolved in CH3CN (10 mL) and 
treated with Selectfluor® (930 mg, 263 mmol).  After 24 h of stirring at 80 °C, the reaction was 
diluted with EtOAc (50 ml) and filtered through Celite. The filtrate was concentrated under 
reduced pressure to afford the product 2.33 in 93% yield (166 mg) as a colorless solid: mp 118–
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120 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.15 (d, J = 8.0 Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 
7.64 (d, J = 8.0 Hz, 1H), 7.55 (t, J = 7.7 Hz, 1H), 4.16 (bs, 2H); 13C NMR (100 MHz, Chloroform-
d) δ 136.2, 135.3, 133.8, 132.1, 130.1, 126.8, 115.9 (t, JCF = 306.1 Hz), 119.5 (q, JCF = 289.9 Hz), 
92.8 – 91.7 (m); 19F NMR (376 MHz, Chloroform-d) δ –82.4 (t, J = 10.9 Hz, 3F), –109.0 (q, J = 
10.9 Hz, 2F); IR (film) νmax 3470, 3099, 1345, 1208, 1180, 1076 cm–1; HRMS (EI) m/z calcd for 
C9H4ClF5O3S (M–H2O)– 321.9490, found 321.9493.  
 
 
 
1,1,1,3,3-pentafluoro-3-tosylpropane-2,2-diol 2.34. To a –78 °C solution of n-BuLi (420 μL, 1.7 
M in hexanes) in THF (4 mL) was added hexamethyldisilazane (149 μL, 0.708 mmol). After 
stirring the reaction for 20 min at –78 °C, a solution of 4-(methylsulfonyl)toluene (100 mg, 0.590 
mmol) in THF (1 ml) was added dropwise. The mixture was stirred for 90 min at –78 °C, and then 
2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (119 μL, 0.855 mmol) was added dropwise. After an 
additional 60 min of stirring at the same temperature the reaction was warmed to room temperature 
and quenched with 1 M H2SO4 (3 mL) and stirred for 60 min. The resultant mixture was extracted 
with CH2Cl2 (5 mL × 3). The combined organics were dried over Na2SO4 and concentrated under 
reduced pressure. The residue was dissolved in CH3CN (10 mL) and treated with Selectfluor® 
(1.05 mg, 2.95 mmol).  After 24 h of stirring at 80 °C, the reaction was diluted with EtOAc (50 
ml) and filtered through Celite. The filtrate was concentrated under reduced pressure to afford the 
product 43 in 71% yield (134 mg) as a colorless solid: mp 73–74 °C; 1H NMR (400 MHz, 
Chloroform-d) δ 7.89 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H), 5.20 (s, 2H), 2.49 (s, 3H); 13C 
NMR (100 MHz, Chloroform-d) δ 148.1 , 131.0 , 130.3 , 129.4 , 122.1 (q, JCF = 287.1 Hz), 116.4 
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(t, JCF = 301.1 Hz), 96.4–91.1 (m), 21.9; 19F NMR (564 MHz, Chloroform-d) δ –82.49 (t, J = 10.8 
Hz), –111.55 (q, J = 10.9 Hz); IR (film) νmax 3433, 3073, 2930, 1338, 1177, 1153, 1074 cm–1; 
HRMS (ESI) m/z calcd for C10H9F5NaO4S (M+Na)+ 343.0034, found 343.0012. 
 
Representative reaction procedure for α,α-difluoromethyl sulfone compounds. A solution of 
1,1,1,3,3-pentafluoro-3-(phenylsulfonyl)propane-2,2-diol 2.31 (30 mg, 0.10 mmol) in H2O/THF 
(0.3 mL/0.3 mL) was treated with Et3N (55 μL, 0.39 mmol) and stirred for 30 min at rt. The 
reaction mixture was quenched with saturated aqueous NH4Cl (1 mL) then extracted with CH2Cl2 
(5 mL x 3). The combined organics were dried over Na2SO4 and concentrated under reduced 
pressure. SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the desired product 2.26 as 
a solid in 89% yield (17 mg).  
 
 
 
((difluoromethyl)sulfonyl)benzene 2.26. See representative reaction procedure. All spectral and 
characterization data matched the reported data.149 
 
 
 
1-((difluoromethyl)sulfonyl)-4-fluorobenzene 2.35. See representative reaction procedure. A 
solution of 1,1,1,3,3-pentafluoro-3-((4-fluorophenyl)sulfonyl)propane-2,2-diol 2.32 (50 mg, 0.15 
mmol) in H2O/THF (0.3 mL/0.3 mL) was treated with Et3N (107 μL, 0.771 mmol). The desired 
product 2.35 was isolated as a solid in 89% yield (28 mg): mp 51–52 °C; 1H NMR (400 MHz, 
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Chloroform-d) δ 8.01 (dp, J = 8.0, 5.0 Hz, 2H), 7.32 (appt, J = 8.3 Hz, 2H), 6.21 (t, J = 53.4 Hz, 
1H); 13C NMR (100 MHz, Chloroform-d) δ 167.5 (d, JCF = 260.0 Hz), 133.9 (d, JCF = 10.2 Hz), 
127.8 (d, JCF = 3.1 Hz), 117.3 (d, JCF = 22.9 Hz), 114.7 (t, JCF = 285.6 Hz);
 19F NMR (376 MHz, 
Chloroform-d) δ –98.8 – –101.2 (m, 1F), –122.4 (d, J = 53.4 Hz, 2F); IR (film) νmax 2921, 2849, 
1347, 1156, 1108, 1077 cm–1; HRMS (EI) m/z calcd for C7H5F3O2S (M)
+ 209.9962, found 
209.9975. 
 
 
 
1-chloro-2-((difluoromethyl)sulfonyl)benzene 2.36. See representative reaction procedure. A 
solution of 1-((2-chlorophenyl)sulfonyl)-1,1,3,3,3-pentafluoropropane-2,2-diol 2.33 (30 mg, 
0.088 mmol) in H2O/THF (0.5 mL/0.5 mL) was treated with Et3N (49 μL, 0.35 mmol). The desired 
product 2.36 was isolated as a solid in 98% yield (19.5 mg): mp 47–49 °C; 1H NMR (400 MHz, 
Chloroform-d) δ 8.16 (dd, J = 8.0, 1.5 Hz, 1H), 7.69 (td, J = 7.9, 1.5 Hz, 1H), 7.62 (d, J = 8.0 Hz, 
1H), 7.55 (t, J = 8.2 Hz, 1H), 6.52 (t, J = 53.8 Hz, 1H); 13C NMR (100 MHz, Chloroform-d) δ 
136.8, 134.5, 134.0, 132.5, 131.5, 128.0, 114.5 (t, JCF = 287.1 Hz); 
19F NMR (376 MHz, 
Chloroform-d) δ –122.9 (d, J = 53.8 Hz, 2F); IR (film) νmax 3087, 2924, 1349, 1172, 1096, 1039 
cm–1; HRMS (ESI) m/z calcd for C7H5ClF2NaO2S (M+Na)
+ 248.9559, found 248.9540. 
 
 
 
1-((difluoromethyl)sulfonyl)-4-methylbenzene 2.37. See representative reaction procedure. A 
solution of 1,1,1,3,3-pentafluoro-3-tosylpropane-2,2-diol 2.34 (40 mg, 0.13 mmol) in H2O/THF 
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(0.3 mL/0.3 mL) was treated with Et3N (70 μL, 0.50 mmol). The desired product 2.37 was isolated 
as a solid in 85% yield (22 mg): mp 68–69 °C; 1H NMR (400 MHz, Chloroform-d) δ 7.87 (d, J = 
8.2 Hz, 2H), 7.44 (d, J = 8.1 Hz, 2H), 6.16 (t, J = 53.5 Hz, 1H), 2.50 (s, 3H); 13C NMR (100 MHz, 
Chloroform-d) δ 147.5, 130.8, 130.4, 128.8, 114.8 (t, JCF = 285.4 Hz), 22.0; 19F NMR (376 MHz, 
Chloroform-d) δ –122.7 (d, J = 53.6 Hz, 2F); IR (film) νmax 2924, 2854, 1343, 1167, 1159, 1077 
cm–1; HRMS (ESI) m/z calcd for C8H8F2NaO2S (M+Na)
+ 229.0103, found 229.0104. 
 
Representative Reaction Procedure for Synthesis of tetrafluorosulfone-based gem-diols. 
To a –78 °C solution of n-BuLi (452 μL, 1.7 M in hexanes) in THF (3 mL) was added 
hexamethyldisilazane (161 μL, 0.768 mmol). After stirring the reaction for 20 min at –78 °C, a 
solution of methyl phenyl sulfone (100 mg, 0.640 mmol) in THF (2 ml) was added dropwise. The 
mixture was stirred for 90 min at –78 °C, and then 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (129 
μL, 0.960 mmol) was added dropwise. After an additional 60 min of stirring at the same 
temperature the reaction was warmed to room temperature and quenched with 1 M H2SO4 (3 mL) 
and stirred for 60 min. The resultant mixture was extracted with CH2Cl2 (5 mL × 3). The combined 
organics were dried over Na2SO4 and concentrated under reduced pressure. The residue was 
dissolved in CH3CN (10 mL) and treated with Selectfluor® (454 mg, 1.28 mmol).  After 24 h of 
stirring at room temperature, the reaction was diluted with EtOAc (50 ml) and filtered through 
Celite. The filtrate was concentrated under reduced pressure to afford the product 2.38 in 90% 
yield (166 mg) as a colorless solid. 
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1,1,1,3-tetrafluoro-3-(phenylsulfonyl)propane-2,2-diol 2.38. See representative reaction 
procedure: mp 75–78 °C; 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 7.8 Hz, 2H), 7.77 (t, J = 7.5 
Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H), 5.35 (d, J = 46.5 Hz, 1H), 5.20 (bs, 2H); 13C NMR (100 MHz, 
CDCl3) δ 136.4, 135.9, 135.5, 131.1, 130.1, 129.8, 121.4 (q, JCF = 289.9 Hz, 1C), 96.9 (d, JCF = 
232.9 Hz, 1C), 93.8–92.5 (m, 1C); 19F NMR (376 MHz, CDCl3) δ –84.9 (d, J = 11.2 Hz, 3F), –
185.6 (dq, J = 46.4, 11.1 Hz, 1F). 
 
 
 
1,1,1,3-tetrafluoro-3-((4-fluorophenyl)sulfonyl)propane-2,2-diol 2.39. To a –78 °C solution of 
n-BuLi (400 μL, 1.7 M in hexanes) in THF (3 mL) was added hexamethyldisilazane (143 μL, 
0.684 mmol). After stirring the reaction for 20 min at –78 °C, a solution of 4-fluorophenyl methyl 
sulfone 14 (100 mg, 0.570 mmol) in THF (2 ml) was added dropwise. The mixture was stirred for 
90 min at –78 °C, and then 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (115 μL, 0.855 mmol) was 
added dropwise. After an additional 60 min of stirring at the same temperature the reaction was 
warmed to room temperature and quenched with 1 M H2SO4 (3 mL) and stirred for 60 min. The 
resultant mixture was extracted with CH2Cl2 (10 mL × 3). The combined organics were dried over 
Na2SO4 and concentrated under reduced pressure. The residue was dissolved in CH3CN (10 mL) 
and treated with Selectfluor® (404 mg, 1.14 mmol).  After 24 h of stirring at room temperature, 
the reaction was diluted with EtOAc (50 ml) and filtered through Celite. The filtrate was 
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concentrated under reduced pressure to afford the product 2.39 in 88% yield (154 mg) as a 
colorless solid: mp 84–86 °C; 1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J = 8.8, 4.9 Hz, 2H), 7.29 
(t, J = 8.4 Hz, 2H), 5.35 (d, J = 46.3 Hz, 1H), 4.99 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 167.4 
(d, JCF = 259.7 Hz, 1C), 133.5 (d, JCF = 10.7 Hz, 2C), 131.4 (d, JCF = 3.0 Hz, 1C), 121.4 (dq, JCF 
= 288.7, 1.5 Hz, 1C), 117.3 (d, JCF = 23.0 Hz, 2C), 97.1 (d, JCF = 232.9 Hz, 1C), 93.8–92.3 (m, 
1C); 19F NMR (564 MHz, CDCl3) δ –84.9 (d, J = 11.1 Hz, 3F), –100.4 (s, 1F) , –185.3 (dq, J = 
33.4, 11.1 Hz, 1F). 
 
 
3-((2-chlorophenyl)sulfonyl)-1,1,1,3-tetrafluoropropane-2,2-diol 2.40. To a –78 °C solution of 
n-BuLi (370 μL, 1.7 M in hexanes) in THF (4 mL) was added hexamethyldisilazane (132 μL, 
0.629 mmol). After stirring the reaction for 20 min at –78 °C, a solution of 2-chlorophenyl methyl 
sulfone 15 (100 mg, 0.525 mmol) in THF (1 ml) was added dropwise. The mixture was stirred for 
90 min at –78 °C, and then 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (106 μL, 0.788 mmol) was 
added dropwise. After an additional 60 min of stirring at the same temperature the reaction was 
warmed to room temperature and quenched with 1 M H2SO4 (3 mL) and stirred for 60 min. The 
resultant mixture was extracted with CH2Cl2 (5 mL × 3). The combined organics were dried over 
Na2SO4 and concentrated under reduced pressure. The residue was dissolved in CH3CN (10 mL) 
and treated with Selectfluor® (372 mg, 1.05 mmol).  After 24 h of stirring at room temperature, 
the reaction was diluted with EtOAc (50 ml) and filtered through Celite. The filtrate was 
concentrated under reduced pressure to afford the product 41 in 79% yield (134 mg) as a colorless 
solid: mp 105–108 °C; 1H NMR (400 MHz, CDCl3) δ 8.14 (d, J = 7.9 Hz, 1H), 7.68 (t, J = 7.3 Hz, 
1H), 7.61 (d, J = 7.8 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 5.82 (d, J = 46.9 Hz, 1H), 4.45 (bs, 2H); 
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13C NMR (100 MHz, CDCl3) δ 136.8, 134.0, 133.7, 133.3, 132.6, 128.1, 121.3 (q, JCF = 287.0 Hz, 
1C), 95.2 (d, JCF = 233.0 Hz, 1C), 94.3–92.9 (m, 1C); 19F NMR (564 MHz, CDCl3) δ –85.0 (d, J 
= 10.5 Hz, 3F), –185.8 (dq, J = 46.2, 9.6 Hz, 1F). 
 
 
 
1,1,1,3-tetrafluoro-3-tosylpropane-2,2-diol 2.41. To a –78 °C solution of n-BuLi (420 μL, 1.7 
M in hexanes) in THF (4 mL) was added hexamethyldisilazane (149 μL, 0.708 mmol). After 
stirring the reaction for 20 min at –78 °C, a solution of 4-(methylsulfonyl)toluene 39 (100 mg, 
0.590 mmol) in THF (1 ml) was added dropwise. The mixture was stirred for 90 min at –78 °C, 
and then 2,2,2-trifluoroethyl 2,2,2-trifluoroacetate (119 μL, 0.855 mmol) was added dropwise. 
After an additional 60 min of stirring at the same temperature the reaction was warmed to room 
temperature and quenched with 1 M H2SO4 (3 mL) and stirred for 60 min. The resultant mixture 
was extracted with CH2Cl2 (5 mL × 3). The combined organics were dried over Na2SO4 and 
concentrated under reduced pressure. The residue was dissolved in CH3CN (10 mL) and treated 
with Selectfluor® (418 mg, 1.18 mmol).  After 24 h of stirring at room temperature, the reaction 
was diluted with EtOAc (50 ml) and filtered through Celite. The filtrate was concentrated under 
reduced pressure to afford the product 2.41 in 78% yield (137 mg) as a colorless solid: mp 97–99 
°C; 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.0 Hz, 3H), 5.31 (d, J = 
46.6 Hz, 1H), 4.90 (bs, 2H), 2.49 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 147.6, 132.3, 130.5 (2C), 
130.3 (2C), 121.3 (q, JCF = 288.2 Hz, 1C), 96.5 (d, JCF = 232.8 Hz, 1C), 93.9–92.4 (m, 1C), 22.1; 
19F NMR (564 MHz, CDCl3) δ –84.90 (d, J = 11.1 Hz, 3F), –185.60 (dq, J = 46.6, 11.1 Hz, 1F). 
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Representative reaction procedure for α,α-difluoromethyl sulfone compounds. A solution of 
1,1,1,3-tetrafluoro-3-(phenylsulfonyl)propane-2,2-diol 2.38 (40 mg, 0.13 mmol) in H2O/THF (0.3 
mL/0.3 mL) was treated with Et3N (73 μL, 0.52 mmol) and stirred for 30 min at rt. The reaction 
mixture was quenched with saturated aqueous NH4Cl (1 mL) then extracted with CH2Cl2 (5 mL x 
3). The combined organics were dried over Na2SO4 and concentrated under reduced pressure. SiO2 
flash chromatography (19:1 hexanes/EtOAc) afforded the desired product 2.42 as a solid in 78% 
yield (18 mg).  
 
 
((fluoromethyl)sulfonyl)benzene 2.38. See representative reaction procedure. All spectral and 
characterization data matched the reported data.150 
 
 
1-fluoro-4-((fluoromethyl)sulfonyl)benzene 2.43. See representative reaction procedure. A 
solution of 1,1,1,3-tetrafluoro-3-((4-fluorophenyl)sulfonyl)propane-2,2-diol 2.39 (30 mg, 0.098 
mmol) in H2O/THF (0.5 mL/0.5 mL) was treated with Et3N (55 μL, 0.39 mmol). The desired 
product 2.43 was isolated as an oil in 79% yield (15 mg): 1H NMR (400 MHz, CDCl3) δ 8.20 (d, 
J = 7.8 Hz, 1H), 7.69–7.64 (m, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 5.46 (d, J = 
47.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 166.7 (d, JCF = 258.2 Hz, 1C), 132.2 (d, JCF = 9.9 
Hz, 2C), 132.0 (d, JCF = 3.1 Hz, 1C), 117.1 (d, JCF = 22.8 Hz, 2C), 92.1 (d, JCF = 219.9 Hz, 1C); 
19F NMR (376 MHz, CDCl3) δ –102.3 (ddt, J = 13.0, 8.3, 4.9 Hz, 1F), –211.5 (t, J = 47.1 Hz, 1F). 
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1-chloro-2-((fluoromethyl)sulfonyl)benzene 2.44. See representative reaction procedure. A 
solution of 3-((2-chlorophenyl)sulfonyl)-1,1,1,3-tetrafluoropropane-2,2-diol 2.40 (30 mg, 0.093 
mmol) in H2O/THF (0.5 mL/0.5 mL) was treated with Et3N (52 μL, 0.37 mmol). The desired 
product 2.44 was isolated as a solid in 62% yield (12 mg): mp 48–50 °C; 1H NMR (400 MHz, 
CDCl3) δ 8.24–8.15 (m, 1H), 7.73–7.5 (m, 2H), 7.56–7.50 (m, 1H), 5.47 (d, J = 48.1 Hz, 2H). 19F 
NMR (376 MHz, CDCl3) δ –211.90 (p, J = 7.2 Hz, 1F).  
 
 
1-((fluoromethyl)sulfonyl)-4-methylbenzene 2.45. See representative reaction procedure. A 
solution of 1,1,1,3-tetrafluoro-3-tosylpropane-2,2-diol 2.41 (30 mg, 0.099 mmol) in H2O/THF (0.3 
mL/0.3 mL) was treated with Et3N (55 μL, 0.39 mmol). The desired product 2.45 was isolated as 
an oil in 68% yield (13 mg). All spectral and characterization data matched the reported data.151  
Representative reaction procedure for α-deutero-α,α-difluoromethyl sulfone compounds. A 
solution of 1,1,1,3,3-pentafluoro-3-(phenylsulfonyl)propane-2,2-diol 2.31 (85 mg, 0.28 mmol) in 
D2O/THF (0.5 mL/0.5 mL) was treated with Et3N (155 μL, 1.11 mmol) and stirred for overnight 
at rt. The reaction mixture was extracted with CH2Cl2 (5 mL x 3). Then, the combined organics 
were dried over Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography 
(19:1 hexanes/EtOAc) afforded the desired product 2.46 as a colorless oil in 74% yield (54 mg).  
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((difluoromethyl-d)sulfonyl)benzene 2.46. See representative reaction procedure. 1H NMR (400 
MHz, Chloroform-d) δ 7.97 (d, J = 7.6 Hz, 2H), 7.78 (t, J = 7.5 Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H); 
13C NMR (100 MHz, Chloroform-d) δ 135.9, 131.8, 130.6, 129.7, 114.7 (tt, JCF = 284.2, JCD = 
30.8 Hz); 19F NMR (376 MHz, Chloroform-d) δ –123.5 (t, J = 8.1 Hz, 2F); IR (film) νmax 2992, 
2916, 1327, 1167, 1121, 1073 cm–1; HRMS (ESI) m/z calcd for C7H5DF2NaO2S (M+Na)
+ 
216.0012, found 216.0038. 
 
 
 
1-((difluoromethyl-d)sulfonyl)-4-fluorobenzene 2.47. See representative reaction procedure. A 
solution of 1,1,1,3,3-pentafluoro-3-((4-fluorophenyl)sulfonyl)propane-2,2-diol 2.32 (50 mg, 0.15 
mmol) in H2O/THF (0.3 mL/0.3 mL) was treated with Et3N (107 μL, 0.771 mmol). The desired 
product 2.47 was isolated as a solid in 80% yield (26 mg): mp 50–51 °C; 1H NMR (400 MHz, 
Chloroform-d) δ 8.01 (dd, J = 8.8, 5.0 Hz, 1H), 7.32 (appt, J = 8.5 Hz, 1H); 13C NMR (100 MHz, 
Chloroform-d) δ 167.5 (d, JCF = 259.9 Hz), 133.9, 127.7, 117.2, 112.9 (tt, JCF = 284.3, JCD = 31.1 
Hz); 19F NMR (376 MHz, Chloroform-d) δ –100.2 – –100.3 (m, 1F), –123.0 (t, J = 7.9 Hz, 2F); IR 
(film) νmax 2922, 2853, 1345, 1191, 1125, 1075 cm–1; HRMS (EI) m/z calcd for C7H4DF3O2S (M)+ 
211.0025, found 211.0035. 
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1-chloro-2-((difluoromethyl-d)sulfonyl)benzene 2.48. See representative reaction procedure. A 
solution of 1-((2-chlorophenyl)sulfonyl)-1,1,3,3,3-pentafluoropropane-2,2-diol 2.33 (40 mg, 0.12 
mmol) in H2O/THF (0.5 mL/0.5 mL) was treated with Et3N (65 μL, 0.47 mmol). The desired 
product 2.48 was isolated as a solid in 96% yield (20 mg): mp 49–50 °C;  1H NMR (400 MHz, 
Chloroform-d) δ 8.17 (d, J = 8.0 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.55 
(t, J = 7.6 Hz, 1H); 13C NMR (100 MHz, Chloroform-d) δ 136.6, 134.4, 133.9, 132.4, 131.5, 127.8, 
114.0 (t, JCF = 284.4, JCD = 31.5 Hz), 
19F NMR (376 MHz, Chloroform-d) δ –123.6 (t, J = 8.4 Hz, 
2F); IR (film) νmax 2921, 2851, 1346, 1191, 1124, 1093 cm–1; HRMS (EI) m/z calcd for 
C7H4DClF2O2S (M)
+ 226.9730, found 226.9738. 
 
 
1-((difluoromethyl-d)sulfonyl)-4-methylbenzene 51. See representative reaction procedure. A 
solution of 1,1,1,3,3-pentafluoro-3-tosylpropane-2,2-diol 43 (50 mg, 0.16 mmol) in H2O/THF (0.3 
mL/0.3 mL) was treated with Et3N (109 μL, 0.781 mmol). The desired product was isolated as a 
solid in 91% yield (29 mg): mp 70–71 °C; 1H NMR (400 MHz, Chloroform-d) δ 7.85 (d, J = 8.1 
Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 2.47 (s, 3H); 13C NMR (100 MHz, Chloroform-d) δ 147.5, 130.7, 
130.4, 128.8, 114.4 (tt, JCF = 282.4, JCD = 30.2 Hz), 21.9; 
19F NMR (376 MHz, Chloroform-d) δ –
123.6 (t, J = 8.4 Hz, 2F); IR (film) νmax 2924, 2849, 1339, 1180, 1123, 1075 cm–1; HRMS (EI) m/z 
calcd for C8H7DF2O2S (M)
+ 207.0276, found 207.0242. 
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 ((fluoromethyl-d2)sulfonyl)benzene 25. A solution of 1,1,1,3-tetrafluoro-3-
(phenylsulfonyl)propane-2,2-diol 13 (35 mg, 0.12 mmol) in D2O/THF (0.5 mL/0.5 mL) was 
treated with Et3N (65 μL, 0.46 mmol) and stirred for 16 h at rt. The reaction mixture was extracted 
with CH2Cl2 (5 mL x 3). Then, the combined organics were dried over Na2SO4 and concentrated 
under reduced pressure. SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the desired 
product 25 as a colorless oil in 75% yield (15 mg): 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 7.8 
Hz, 2H), 7.70 (t, J = 7.5 Hz, 1H), 7.58 (t, J = 7.8 Hz, 2H); 19F NMR (376 MHz, CDCl3) δ –213.3 
(p, J = 6.8 Hz, 1F). 
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CHAPTER 3 
DEVELOPMENT OF GABAB AGONISTS 
3.1. GABAB Receptor 
GABA is the major inhibitory neurotransmitter in the central nervous system (Figure 3.1). 
Stimulation of the GABAB receptor, a G-protein coupled receptor, inhibits cyclic-AMP 
production.152 The two major types of GABA receptors are GABAA and GABAB and both are 
validated targets for drug discovery.153 The GABAA receptors are ion channels and can be 
controlled by three classes of pharmaceuticals, the barbiturates, the benzodiazepines, and the 
newer non-benzodiazepine sedatives, such as zaleplon and zopiclone.154 Baclofen, the only FDA 
approved GABAB agonist, is indicated for the treatment of spasticity associated with spinal cord 
injury, cerebral palsy and multiple sclerosis (Figure 3.1). Baclofen has been reported to inhibit 
transient lower esophageal sphincter (LES) relaxations which indicates that it could help manage 
gastroesophageal reflux disease.155 Baclofen exerts a dose-dependent antinociceptive effect, 
increases pain threshold156 and enhances morphine analgesia.157 GABAB agonists have been 
reported to reduce dopamine levels in the ventral striatum and thereby reduce self-administration 
of cocaine,158 alcohol,159 and cigarettes.160 The various potential applications of GABAB agonists 
are not matched with an increased number of agonists in the market and in clinical trials.  
 
Figure 3.1. Structures of GABA and Baclofen 
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3.2. Fluorinated GABAB Receptor Agonists 
A novel series of fluorinated GABAB agonists were reported by our group.
16 The most 
potent compound in the series is compound 3.1 with an EC50 of 24.9 μM compared to an EC50 of 
2.8 μM for baclofen (Figure 3.2). The core structure of these new agonists is a difluoromethyl β-
hydroxy ketone which is distinct from all other known GABAB ligands which display the GABA 
core structure. This scaffold presents a distinct opportunity to identify new structure-activity 
relationships for agonist activity for the GABAB receptor. 
 
Figure 3.2. EC50 of the lead compound and Baclofen 
Most known GABAB agonists have a carboxylic acid group or one of its bioisosteres. In 
compounds with the difluoromethyl β-hydroxy ketone, the presence of the difluoromethyl group 
stabilizes the hydrated form of the keto group which can act as a carboxylic acid bioisostere 
(Figure 3.3). Figure 3.4 shows the lead compound 3.1 docked in the active site of GABAB receptor 
as the hydrated form. The docking studies show that the diol group of this compound overlaps with 
baclofen's carboxylic acid group inside the active site. This theory provides an insight on the role 
fluorination plays in the activity of these compounds.   
 
Figure 3.3. The equilibrium between the ketone and the hydrated forms of compound 1 
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Figure 3.4. a) Crystal structure of Baclofen inside the binding pocket of GABAB receptor, b) 
compound 3.1 docked in the binding pocket of GABAB receptor 
 
 
3.3. Lead Compound Binding Profile  
The lead compound was screened on a range of neurotransmitter receptors (Table 3.1) to 
determine its receptor binding profile (data was provided by the National Institute of Mental 
Health’s Psychoactive Drug Screening Program). Compound 3.1 proved selective for GABAB over 
GABAA (EC50 >100 µM). The compound also yielded inhibition of binding of 30% or less against 
at all of the tested receptor, suggesting that compound 3.1 is a selective GABAB receptor agonist. 
  
Trp278 
Glu349 
His170 
Tyr250 Tyr279 
Trp65 
Gly151 
Ser130 
Cys129 
Cys103 
Ser153 
His170 
Trp278 
Ser153 Ser130 
Tyr250 
Tyr279 
Ile276 
Trp65 
Phe202 
Glu349 
a) b) 
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Table 3.1. Primary radioligand binding assays. 
Serotonin receptors 
5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-
HT2C, 5-HT3, 5-HT6, 5-HT7 
Biogenic amine transporters SERT, NET 
Adrenoceptors α1A, α 1B, α1D, β1, β3 
Cannabinoid CB1, CB2 
Opioid receptors MOR, KOR, DOR 
Dopamine receptors D1, D2, D3, D5 
Histamine receptors H1, H2, H3, H4 
Sigma receptors Sigma1, Sigma2 
Muscarinic receptors M1, M2, M3, M4, M5 
 
3.4. Analogues at the para Position on the Phenyl Ring  
To evaluate the tolerance for variations at the para position on the phenyl ring, the p-acetyl 
group was removed 3.2, replaced with a chlorine atom 3.3 or an ethyl group 3.4 (Figure 3.5). The 
target compounds 3.2–3.4 were synthesized using trifluoroacetate-release aldol reaction of 
pentafluoro-gem-diol 3.5 with benzaldehyde, p-chlorobenzaldehyde, and p-ethyl benzaldehyde 
(Scheme 3.1). With these analogues on hand, a cell line that expresses human GABAB receptor 
was used to measure GABAB agonist activity. Activation of GABAB receptors leads to inhibition 
of cAMP production. Forskolin (FSK) is used to activate adenylyl cyclase (AC) to produce cAMP. 
The addition of a GABAB agonist suppresses this activation of cAMP production and so the assay 
measures % block of FSK activation of AC.16 All three compounds were inactive even at 100 µM 
concentration. This suggests that the acetyl group in essential for binding. 
65 
 
 
Figure 3.5. Analogues at the para position on the phenyl ring 
 
 
Scheme 3.1. Synthesis of compounds 3.2–3.4 
3.5. Monofluorinated Analogues  
Compound 3.6 was prepared to understand if a monofluoromethyl group could replace the 
difluoromethyl group (Scheme 3.2). It is already known that the non-fluorinated analogue 3.7 is 
inactive as a GABAB agonist, presumably because this compound predominantly exists in the keto 
form. The tertafluorinated gem-diol 2.21 (see section 2.4) was reacted with p-acetylbenzaldehyde 
to generate analogue 3.6. When evaluated in the GABAB assay, compound 3.6 exhibits an EC50 of 
12.2 µM, thus being twice as active as the difluorinated analogue 3.1. The enhanced activity of 
compound 3.6 could be a result of it exhibiting better physicochemical properties, as the removal 
of one fluorine makes the compound less lipophilic.  
66 
 
 
Scheme 3.2. Synthesis and GABAB activity of monofluorinated analogues 
The monofluorinated analogue 3.6 was tested as a mixture of enantiomers. In an attempt 
to better understand the structure activity relationship, the syn- and anti-diastereomers were 
purified using preparative TLC and will be tested for GABAB activity separately. The crystal 
structure of the syn-diastereomer 3.8 was obtained to confirm the structure (Figure 3.6).    
 
 
 
Figure 3.6. Crystal structure of the syn-monofluoro analogue 
To further investigate if the monofluorinated compounds are more active than teir 
difluorinated counterparts, other monofluorinated analogues were designed and synthesized 
(Figure 3.7). The adamantly group was retained because a lipophilic group at this position is 
required. On the other hand, on the alcohol side it's more flexible, so a styrene 3.9, a p-methoxy-
phenyl 3.10, and a hexenyl analogue 3.11 were prepared. The analogues will be tested for their 
GABAB activity to identify additional structure-activity relationship at this position. 
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Figure 3.7. Monofluorinated analogues 3.9–3.11 
3.6. Analogues at the β-Position     
Next, we are interested in exploring analogues with various groups on the β-position. We 
aim to add a methyl group at the β-position or exchange the hydroxy group with an amine methyl, 
oxirane, or oxazoline group. To accomplish these replacements, halohydrins were proposed as 
intermediates that can be utilized to access the analogues of interest (Figure 3.8). Halohydrins can 
be debrominated to synthesize the tertiary methyl alcohol analogue and can be cyclized to the 
epoxide and oxazoline analogues. 
 
Figure 3.8. Analogues at the β-position 
3.7. Synthesis of Fluorinated Halohydrins  
Halohydrins are versatile building blocks with applications in the synthesis of 
pharmaceuticals, agrochemicals, plasticizers, dyes intermediates and others. Fluorinated 
halohydrins are underexplored despite their potential. Very few reports of α,α-difluoro-halohydrin 
can be found in literature and are limited to polyfluorinated compounds.161-164 To our knowledge 
the only reports of synthesis of α,α-difluoro-β-keto bromohydrin and chlorohydrins were by 
Zeifman et al. and Krespan (Scheme 3.3).165-166 Both methods are limited by their narrow scope 
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of application since they are reports of self-condensation of polyfluorinated haloketones. 
Furthermore, the use of toxic reagents like nickel tetracarbonyl, cadmium and mercury chloride 
renders these methods impractical.  
 
Scheme 3.3. Synthetic approaches to (a) α,α-difluoro-β-keto bromohydrin and (b) chlorohydrins 
 
The α,α-difluoroenolates generated during the release of trifluoroacetate can react with 
aldehydes to produce α,α-difluoro-β-hydroxy ketones,107 and with α-trifluoromethyl ketones to 
provide α,α-difluoro-β-hydroxy-β-trifluoromethyl ketones.105 Accordingly, we hypothesized that 
this method will be compatible with α-haloketones and will go through aldol reaction to generate 
the versatile fluorinated halohydrins. However, relatively few examples of halohydrin synthesis 
through aldol-type reactions are reported in literature.167-168 This fact is probably due to competing 
reactions of α-haloketones; including nucleophilic replacement of the halide,169 terminal epoxide 
formation170 or internal epoxide formation through Darzens reaction,171 as well as rearrangement 
reactions like Favorskii reaction,172 Feist–Benary reaction,173 and 1,4-diketone formation (Scheme 
3.4).174 Thus, chemoselectivity is essential for the success of our synthetic plan. Fortunately, due 
to the mildness of the conditions of trifluoroacetate-release, α,α-difluoroenolates add selectively 
to the carbonyl generating α,α-difluoro-β-keto halohydrins (Scheme 3.5).  
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Scheme 3.4. Aldol-type reactions of α-Haloketones 
 
Scheme 3.5. Aldol reactions of α-haloketones with α,α-difluoroenolates from trifluoroacetate 
release 
 
3.8. Fluorinated Halohydrins Via Trifluoroacetate-Release Reaction  
Our efforts to explore the optimum conditions for this transformation revealed that the use 
of LiBr is essential to drive the reaction, nonetheless, the protonated enolate remained a major by-
product. Fortunately, using an extra equivalent of the ketone and increasing the reaction 
concentration to 0.5 M eliminated this by-product and a quantitative transformation was achieved 
(Table 3.2). On the other hand, increasing the equivalents of triethylamine was detrimental to the 
yield, partially due to epoxide formation and promoting the formation of the α-haloketone self-
adduct. Interestingly, applying the optimized reaction conditions to unhalogenated ketones, 
including acetophenone and acetone, resulted in poor yields; presumably because they lacked the 
activation of the carbonyl group by the halogen on the α-position. 
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Table 3.2. Optimization of the aldol reactions of α-haloketones with α,α-difluoroenolates 
 
 
We sought to explore the scope of this reaction to various α-bromoketones and α-
chloroketones. During this investigation, we found that it is essential to match the lithium salt 
counterion to the α-haloketone halogen to achieve satisfactory yields. This observation is probably 
due to halogen exchange; as the by-products expected from this side reaction were observed by 
mass spectroscopy. Hence, LiBr was used with α-bromoketones and LiCl was used with α-
chloroketones. Aromatic, heteroaromatic and aliphatic pentafluoro-gem-diols reacted with α-
bromoketones to produce α-bromohydrins 3.18-3.24 in good to excellent yields (Scheme 3.6). In 
case of compound 3.24, the halohydrin was isolated in 57% yield, most likely due to the steric 
encumbrance of the adamantly group. 
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Scheme 3.6. Aldol reactions of α-bromoketones 
 
Next, we treated mixtures of pentafluoro-gem-diols and α-chloroketones in THF with LiCl 
and Et3N and generated the α-chlorohydrins 3.25-3.32 (Scheme 3.7).  As with α-bromoketones, a 
wide range of substituted pentafluoro-gem-diols were found to be compatible with this process. 
Phenyl and substituted phenyl α-chloroketones reacted under these conditions in good yields. On 
the other hand, chloroacetone, an aliphatic α-chloroketone, reacted to give compounds 3.27 and 
3.28 in slightly lower yields than the aromatic α-chloroketones.  
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Scheme 3.7. Aldol reactions of α-chloroketones 
 
Despite being compatible with various α-halohydrins, this method didn’t give the expected 
product in the case of the electron rich α-bromoketone 3.34. The addition of compound 3.34 to 
pentafluoro-gem-diols 3.33 and 3.17 led to the formation of the epoxides 3.35 and 3.36 (Scheme 
3.8). Moreover, increasing the amount of triethylamine used from 1.2 to 2 equivalents almost 
doubled the yield of epoxide 3.36 formation. On the other hand, electron deficient α-haloketones 
produce predominantly halohydrins when reacted with pentafluoro-gem-diols. Furthermore, when 
the resulting electron poor bromohydrins were further treated with triethylamine, they mostly 
remained unreacted and epoxides were isolated in poor yields. Accordingly, when compound 3.24 
was treated with 3 equivalents of triethylamine for 24 hours, it resulted in the formation of the 
epoxide 3.27 in 29% yield.  
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Scheme 3.8. Epoxide formation with electron rich α-bromoketone 
 
When the same conditions were attempted with α-haloketones in which the halogenated α-
carbon is a secondary carbon, namely 2-bromopropiophenone (3.38) and 3-chloro-2-butanone 
(3.39), no halohydrin formation was observed (Scheme 3.9). Instead the fluoroenolates remained 
unreacted until they were quenched to form the α,α-difluoromethyl ketones as the major products. 
However, chlorocyclohexanone (3.40) reacted under these conditions to produce chlorohydrin 
3.41 in a good yield. The reactivity of 25 is probably driven by the release of the ring strain. 
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Scheme 3.9. Reactions of α-haloketones with a secondary halogenated α-carbon 
 
The trifluoroacetate-release aldol reaction with α-haloketones has substantial potential in 
accessing fluorinated halohydrin compounds. The products of this reaction can be further modified 
to access other interesting functionalities. Debromination of bromohydrins creates tertiary methyl 
alcohols, a group of compounds that was previously inaccessible using this approach due to the 
lack of reactivity of methyl ketones under these reaction conditions. Under radical debromination 
conditions compound 3.42 was formed in a fair yield (Scheme 3.10). Furthermore, halohydrins 
are known intermediates in the synthesis of heterocycles like epoxides and oxazolines. Examples 
of epoxide synthesis can be found in scheme 4. Moreover, halohydrin 3.19 was found to react with 
acetonitrile in the presence of BF3·Et2O and CsF and oxazoline 3.43 was retrieved in 42% yield 
(Scheme 6). 
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Scheme 3.10. Reactions of α-bomoketones 
 
3.9. Biological Evaluation of Fluorinated Halohydrins and Their Derivatives 
We are interested to find if the halohydrin analogues would display activity at GABAB 
receptors. Whereas halohydrins are generally not considered ideal for biological applications, they 
have been used as probes in structure-activity relationship studies.175-176 Hence, halohydrins 3.18-
3.33 were tested for agonist activity at the GABAB receptor according to the previously reported 
procedures (Table 3.3).16 Several compounds demonstrated activity at the GABAB receptor that 
ranged from 30% to 90% at 100 µL. Bromohydrins are known to revert to their epoxide 
counterparts in physiological conditions;175 thus the activity demonstrated by bromohydrins are 
potentially precipitated by the epoxides formed in situ. When comparing the activity of 
bromohydrin 3.24 to its epoxide analogue 3.27, we found that the epoxide was the more active 
form (Figure 3.9). On the other hand, the correspondent noncyclic compound 3.42 is more active 
than the cyclic agent 3.27, suggesting that a hydrogen bond donor is beneficial for the activity. 
However, the methyl group is essential to preserve the activity as demonstrated by the lack of 
activity of the non-methylated alcohol 3.44. The trifluoroacetate-release aldol reaction provides 
access to this interesting class of biologically active compounds; and future studies will target the 
investigation of the activity of fluorinated tertiary methyl alcohols as GABAB agonists.  
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Table 3.3. Agonist activity of halohydrins at GABAB receptor 
Compound GABAB agonist activity 
3.18 50% 
3.19 nd 
3.20 nd 
3.21 nd 
3.22 30% 
3.23 80% 
3.24 nd 
3.25 nd 
3.26 nd 
3.27 50% 
3.28 90% 
3.29 90% 
3.30 40% 
3.31 nd 
3.32 nd 
3.33 40% 
nd is not determined 
 
 
 
Figure 3.9. GABAB agonist activity of halohydrin 3.24 and its derivatives 
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3.10. Experimental Details 
Representative Reaction Procedure for Trifluoroacetate Release/Aldol Reaction. To a 
solution of 1-adamantan-1-yl-2,2,4,4,4-pentafluoro-3,3-dihydroxybutan-1-one 3.5 (50 mg, 0.15 
mmol), benzaldehyde (31 μL, 0.30 mmol), and LiBr (40 mg, 0.46 mmol) in THF (500 μL), was 
added Et3N (32 μL, 0.23 mmol) dropwise. The mixture was stirred for 30 minutes at room 
temperature, then quenched with saturated aqueous NH4Cl (3 mL) and extracted with EtOAc (5 
mL × 3). The organics were dried over Na2SO4 and concentrated under reduced pressure. SiO2 
flash chromatography (5% EtOAc in hexanes) afforded the title compound 3.2 in 88% yield (43 
mg) as a colorless solid.  
 
1-(adamantan-1-yl)-2,2-difluoro-3-hydroxy-3-phenylpropan-1-one 3.2. See representative 
reaction procedure: mp 78–80 °C; 1H NMR (400 MHz, CDCl3) δ 7.44–7.40 (m, 2H), 7.39–7.33 
(m, 3H), 5.25 (ddd, J = 17.4, 7.1, 5.1 Hz, 1H), 2.85 (d, J = 5.1 Hz, 1H), 2.01 (s, 3H), 1.87 (d, J = 
2.4 Hz, 6H), 1.70 (q, J = 12.3 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 205.9 (dd, JCF = 29.0, 26.1 
Hz, 1C), 135.1 (d, JCF = 2.2 Hz, 1C), 129.0, 128.4 (2C), 128.2 (2C), 116.6 (dd, JCF = 266.6, 259.5 
Hz, 1C), 73.3 (dd, JCF = 27.6, 23.4 Hz, 1C), 46.9 (t, JCF = 2.4 Hz, 1C), 36.9 (3C), 36.5 (3C), 27.7 
(3C); 19F NMR (377 MHz, CDCl3) δ –108.2 (dd, J = 284.5, 6.9 Hz, 1F), –119.0 (dd, J = 284.5, 
17.4 Hz, 1F); IR (film) νmax 3511, 2906, 2852, 1712, 1454, 1056 cm–1; HRMS (ESI) m/z calcd for 
C19H22F2O2Cs (M+Cs)
+ 453.0642, found 453.0631. 
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1-(adamantan-1-yl)-3-(4-chlorophenyl)-2,2-difluoro-3-hydroxypropan-1-one 3.3. See 
representative reaction procedure. To a solution of 1-adamantan-1-yl-2,2,4,4,4-pentafluoro-3,3-
dihydroxybutan-1-one 3.5 (100 mg, 0.304 mmol), 4-chlorobenzaldehyde (87 mg, 0.61 mmol), and 
LiBr (132 mg, 1.52 mmol) in THF (500 μL), was added Et3N (51 μL, 0.37 mmol) dropwise. SiO2 
flash chromatography (5% EtOAc in hexanes) afforded the title compound 3.3 as a colorless solid 
(98 mg, 91% yield): mp 138–139 °C; 1H NMR (400 MHz, CDCl3) δ 7.35 (s, 4H), 5.23 (ddd, J = 
17.7, 6.6, 4.9 Hz, 1H), 2.95 (d, J = 5.0 Hz, 1H), 2.03 (s, 3H), 1.89 (d, J = 2.2 Hz, 6H), 1.71 (q, J = 
12.2 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 205.7 (dd, JCF = 29.3, 26.1 Hz, 1C), 134.9, 133.6 (d, 
JCF = 2.1 Hz, 1C), 129.6 (2C), 128.5 (2C), 116.3 (dd, JCF = 267.5, 259.4 Hz, 1C), 72.6 (dd, JCF = 
28.0, 23.4 Hz, 1C), 46.9 (dd, JCF = 3.1, 1.9 Hz, 1C), 36.9 (dd, JCF = 2.5, 1.5 Hz, 3C), 36.4 (3C), 
27.7 (3C); 19F NMR (376 MHz, CDCl3) δ –107.4 (dd, J = 288.8, 6.0 Hz, 1F), –119.9 (dd, J = 
288.8, 17.8 Hz, 1F); IR (film) νmax 3494, 2910, 2856, 1712, 1494, 1063, 800 cm–1; HRMS (ESI) 
m/z calcd for C19H21Cl2F2O2 (M+Cl)
– 389.0887, found 389.0861. 
 
1-(adamantan-1-yl)-3-(4-ethylphenyl)-2,2-difluoro-3-hydroxypropan-1-one 3.4. See 
representative reaction procedure. To a solution of 1-adamantan-1-yl-2,2,4,4,4-pentafluoro-3,3-
dihydroxybutan-1-one 3.5 (50 mg, 0.15 mmol), 4-ethylbenzaldehyde (42 μL, 0.30 mmol), and 
LiBr (40 mg, 0.46 mmol) in THF (500 μL), was added Et3N (32 μL, 0.23 mmol) dropwise. SiO2 
flash chromatography (5% EtOAc in hexanes) afforded the title compound 3.4 as a colorless solid 
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(44 mg, 83% yield): mp 102–103 °C ; 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 7.9 Hz, 2H), 7.21 
(d, J = 8.1 Hz, 2H), 5.21 (ddd, J = 17.7, 7.1, 4.6 Hz, 1H), 2.77 (d, J = 5.0 Hz, 1H), 2.66 (q, J = 7.7 
Hz, 2H), 2.01 (s, 3H), 1.88 (s, 6H), 1.70 (q, J = 12.3 Hz, 6H), 1.23 (t, J = 7.6 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 205.9 (dd, JCF = 29.3, 25.8 Hz, 1C), 145.2, 132.4 (d, JCF = 1.9 Hz, 1C), 128.2 
(2C), 127.9 (2C), 116.7 (dd, JCF = 266.6, 258.9 Hz, 1C), 73.2 (dd, JCF = 27.8, 23.4 Hz, 1C), 46.9 
(t, JCF = 1.9 Hz, 1C), 36.9 (3C), 36.5 (3C), 28.8, 27.8 (3C), 15.7;
 19F NMR (376 MHz, CDCl3) δ –
108.00 (d, J = 284.0 Hz, 1F), –119.26 (dd, J = 285.1, 18.0 Hz, 1F); IR (film) νmax 3502, 2909, 
2851, 1712, 1453, 1273, 1052 cm–1; HRMS (ESI) m/z calcd for C21H26F2O2Cs (M+Cs)
+ 481.0955, 
found 481.0947. 
 
3-(4-acetylphenyl)-1-(adamantan-1-yl)-2-fluoro-3-hydroxypropan-1-one 3.6. See 
representative reaction procedure. To a solution of 1-(adamantan-1-yl)-2,4,4,4-tetrafluoro-3,3-
dihydroxybutan-1-one 2.21 (100 mg, 0.322 mmol), p-acetylbenzaldehyde (95 mg, 0.65 mmol), 
and LiBr (140 mg, 1.61 mmol) in THF (2 ml), was added Et3N (54 μL, 0.39 mmol) dropwise. SiO2 
flash chromatography (5% EtOAc in hexanes) afforded the title compound 3.6 in 60% yield (67 
mg). 
Syn-diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 
2H), 5.26 (dd, J = 21.2, 4.0 Hz, 1H), 5.15 (dd, J = 47.3, 4.0 Hz, 1H), 2.61 (s, 3H), 2.00 (s, 3H), 
1.75 (s, 6H), 1.74–1.53 (m, 6H); 19F NMR (471 MHz, CDCl3) δ –196.6 (dd, J = 47.4, 21.2 Hz, 
1F). 
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Anti-diastereomer: 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.3 Hz, 2H), 7.51 (d, J = 8.2 Hz, 
2H), 5.16 (d, J = 7.2 Hz, 1H), 5.09–4.94 (m, 1H), 2.61 (s, 3H), 2.03 (s, 3H), 1.83 (q, J = 13.0 Hz, 
6H), 1.78–1.65 (m, 6H); 19F NMR (471 MHz, CDCl3) δ –190.4 (dd, J = 46.8, 9.5 Hz, 1F). 
  
(E)-1-(adamantan-1-yl)-2-fluoro-3-hydroxy-5-phenylpent-4-en-1-one 3.9. See representative 
reaction procedure. To a solution of 1-(adamantan-1-yl)-2,4,4,4-tetrafluoro-3,3-dihydroxybutan-
1-one 2.21 (100 mg, 0.322 mmol), cinnamaldehyde (81 μL, 0.65 mmol), and LiBr (140 mg, 1.61 
mmol) in THF (2 ml), was added Et3N (54 μL, 0.0.39 mmol) dropwise. SiO2 flash chromatography 
(5% EtOAc in hexanes) afforded the title compound 3.9 in  67% yield (71 mg): 1H NMR (500 
MHz, CDCl3) δ 7.43–7.38 (m, 2H), 7.35 (t, J = 7.5 Hz, 2H), 7.31–7.25 (m, 1H), 6.74 (dd, J = 15.9, 
4.9 Hz, 1H), 6.26 (ddd, J = 22.6, 16.0, 6.4 Hz, 1H), 5.09 (ddd, J = 47.5, 18.9, 4.9 Hz, 1H), 4.85–
4.70 (m, 1H), 2.65 (d, J = 26.1 Hz, 1H), 2.08 (s, 3H), 1.93 (s, 6H), 1.75 (q, J = 11.9 Hz, 6H); 13C 
NMR (126 MHz, CDCl3) δ 211.2 (d, JCF = 17.9 Hz, 1C), 210.9 (d, JCF = 17.8 Hz, 1C)*, 136.3, 
136.2*, 133.4, 133.3*, 128.8 (2C), 128.7(2C)*, 128.2, 128.2*, 126.8 (2C), 126.8 (2C)*, 125.8 (d, 
JCF = 3.9 Hz), 125.7 (d, JCF = 4.6 Hz)*, 94.1 (d, JCF = 161.8 Hz), 92.6 (d, JCF = 159.0 Hz)*, 72.6 
(d, JCF = 20.9 Hz), 72.1 (d, JCF = 22.8 Hz)*, 37.2 (d, JCF = 2.4 Hz, 3C), 37.1 (d, JCF = 2.6 Hz, 3C)*, 
36.5 (3C), 29.8, 27.8 (3C); 19F NMR (376 MHz, CDCl3) δ –195.4 (dd, J = 47.6, 13.6 Hz, 1F), –
199.2 (dd, J = 47.8, 19.1 Hz, 1F). 
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1-(adamantan-1-yl)-2-fluoro-3-hydroxy-3-(4-methoxyphenyl)propan-1-one 3.10. See 
representative reaction procedure. To a solution of 1-(adamantan-1-yl)-2,4,4,4-tetrafluoro-3,3-
dihydroxybutan-1-one 2.21 (100 mg, 0.322 mmol), p-methoxybenzaldehyde (88 mg, 0.65 mmol), 
and LiBr (140 mg, 1.61 mmol) in THF (2 ml), was added Et3N (54 μL, 0.0.39 mmol) dropwise. 
SiO2 flash chromatography (5% EtOAc in hexanes) afforded the title compound 3.10 in  80% yield 
(86 mg): 1H NMR (400 MHz, CDCl3) δ 7.29 (t, J = 9.2 Hz, 2H), 6.88 (t, J = 7.9 Hz, 2H), 5.20 – 
5.08 (m, 1H), 5.07–4.96 (m, 1H), 3.80 (d, J = 2.9 Hz, 3H), 3.03 (d, J = 64.9 Hz, 1H), 2.00 (d, J = 
13.0 Hz, 3H), 1.86–1.60 (m, 12H); 13C NMR (100 MHz, CDCl3) δ 211.6 (d, JCF = 17.3 Hz, 1C), 
210.2 (d, JCF = 16.9 Hz, 1C)*, 159.7, 159.7*, 131.1 (d, JCF = 1.4 Hz, 1C), 130.1 (d, JCF = 4.4 Hz, 
1C)*, 128.4 (d, JCF = 1.4 Hz, 2C), 128.4 (d, JCF = 1.0 Hz, 2C)*, 114.0 (2C), 113.9 (2C)*, 93.3 (d, 
JCF = 134.0 Hz, 1C), 91.5 (d, JCF = 131.6 Hz, 1C)*, 73.2 (d, JCF = 20.2 Hz, 1C), 72.7 (d, JCF = 23.6 
Hz, 1C)*, 55.4, 55.4*, 36.9 (d, JCF = 2.2 Hz, 3c), 36.7 (d, JCF = 1.9 Hz, 3C)*, 36.5 (3C), 36.4 
(3C)*, 29.8, 27.7 (3C), 27.6 (3C)*. 
 
(E)-1-(adamantan-1-yl)-2-fluoro-3-hydroxyoct-4-en-1-one 3.11. See representative reaction 
procedure. To a solution of 1-(adamantan-1-yl)-2,4,4,4-tetrafluoro-3,3-dihydroxybutan-1-one 
2.21 (10 mg, 0.322 mmol), (E)-hex-2-enal (75 μL, 0.65 mmol), and LiBr (140 mg, 1.61 mmol) in 
THF (2 ml), was added Et3N (54 μL, 0.0.39 mmol) dropwise. SiO2 flash chromatography (5% 
EtOAc in hexanes) afforded the title compound 3.11 in  73% yield (69 mg): 1H NMR (500 MHz, 
CDCl3) δ 5.78 (dq, J = 14.9, 7.2 Hz, 1H), 5.48 (td, J = 15.2, 6.9 Hz, 1H), 4.96 (dd, J = 47.9, 4.5 
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Hz, 1H), 4.51 (ddt, J = 24.3, 13.7, 6.1 Hz, 1H), 2.47 (s, 1H), 2.04 (s, 3H), 1.88 (s, 6H), 1.72 (q, J 
= 12.0 Hz, 6H), 1.39 (h, J = 7.3 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
211.1 (d, JCF = 17.3 Hz. 1C), 210.7 (d, JCF = 17.9 Hz, 1C)*, 135.8, 135.4*, 126.6 (d, JCF = 3.9 Hz, 
1C), 126.5 (d, JCF = 4.8 Hz, 1C)*, 72.6 (d, JCF = 20.7 Hz, 1C), 72.3 (d, JCF = 22.7 Hz, 1C)*, 37.2 
(d, JCF = 2.4 Hz, 3C), 37.1 (d, JCF = 2.5 Hz, 3C)*, 36.6 (3C), 36.5 (3C)*, 34.5, 34.5*, 27.8 (3C), 
22.2, 13.8, 13.8*; 19F NMR (376 MHz, CDCl3) δ –196.3 (dd, J = 47.7, 14.6 Hz, 1F), –199.2 (dd, 
J = 47.8, 20.9 Hz, 1F). 
Representative Reaction Procedure for Trifluoroacetate-release/Aldol Reaction with α-
Haloketones. To a solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalen-2-yl)-butan-1-
one (300 mg, 0.937 mmol), 2-Bromo-4'-chloroacetophenone (438 mg, 1.87 mmol), and LiBr (244 
mg, 2.81 mmol) in THF (2 mL) was added Et3N (157 μL, 1.12 mmol) dropwise at 0 °C. The 
mixture was warmed to room temperature and stirred for 30 minutes. The mixture was quenched 
with saturated aqueous NH4Cl (3 mL) and extracted with EtOAc  (3 × 5 mL). The organics were 
dried over Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (19:1 
hexanes/EtOAc) afforded the product 3.18 in 87% yield (358 mg) as a colorless solid.  
 
4-bromo-3-(4-chlorophenyl)-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)butan-1-one 3.18. 
See representative reaction procedure: mp 131–133 °C; 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 
1H), 7.97 (dd, J = 13.9, 8.4 Hz, 2H), 7.87 (d, J = 8.9 Hz, 2H), 7.65 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 
7.57 (ddd, J = 8.1, 6.8, 1.3 Hz, 1H), 7.51 (d, J = 8.4 Hz, 2H), 7.42–7.36 (m, 2H), 4.22 (q, J = 11.2 
Hz, 2H), 3.58 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 190.3 (dd, JCF = 29.9, 27.8 Hz, 1C), 136.2, 
135.3, 135.2, 133.8 (dd, JCF = 5.7, 4.1 Hz, 1C), 132.2, 130.4 (2C), 129.7, 128.8 (2C), 128.5 (2C), 
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128.4, 127.9, 127.2, 125.1 (t, JCF = 2.0 Hz, 1C), 116.2 (dd, JCF = 266.3, 264.2 Hz, 1C), 78.1 (t, JCF 
= 24.8 Hz, 1C), 37.7 (t, JCF = 3.5 Hz, 1C); 
19F NMR (376 MHz, CDCl3) δ –105.7 (d, JFF = 274.5 
Hz, 1F), –107.2 (d, JFF = 274.4 Hz, 1F); IR (film) νmax 3518, 3061, 2961, 2925, 1686, 1626, 1493, 
1094, 755 cm–1; HRMS (ESI) m/z calcd for C20H14BrClF2O2 (M+Na)
+ 460.9726, found 460.9740. 
 
4-bromo-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)-3-phenylbutan-1-one 3.19. See 
representative reaction procedure. . To a solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)- butan-1-one (100 mg, 0.312 mmol), 2-bromoacetophenone (124 mg, 0.624 
mmol), and LiBr (135 mg, 1.56 mmol) in THF (500 μL), was added Et3N (53 μL, 0.37 mmol) 
dropwise. SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.19 in 88% 
yield (98 mg) as a solid: mp 64–65 °C; 1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H), 7.95 (dd, J = 
14.2, 8.5 Hz, 2H), 7.85 (dd, J = 8.4, 4.6 Hz, 2H), 7.63 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.61–7.53 
(m, 4H), 7.46–7.33 (m, 2H), 4.26 (s, 2H), 3.53 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 190.6 (dd, 
JCF = 29.9, 27.7 Hz, 1C), 136.5, 136.0, 133.7 (dd, JCF = 5.9, 4.0 Hz, 1C), 132.2, 130.6, 130.3, 
129.5, 129.0, 128.5 (2C), 128.2, 127.8, 127.0 (2C), 127.0, 125.2–125.1 (m, 1C), 116.5 (dd, JCF = 
266.3, 264.2 Hz, 1C), 78.2 (t, JCF = 24.8 Hz, 1C), 38.0 (t, JCF = 3.6 Hz, 1C); 
19F NMR (376 MHz, 
CDCl3) δ –106.0 (d, JFF = 270.6 Hz, 1F), –107.4 (d, JFF = 270.7 Hz, 1F); IR (film) νmax 3519, 3061, 
2925, 1688, 1626, 1450, 1108 cm–1; HRMS (ESI) m/z calcd for C20H15BrF2O2 (M+H)
+ 405.0296, 
found 405.0306. 
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4-bromo-3-(3,4-dichlorophenyl)-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)butan-1-one 
3.20. See representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)-butan-1-one (100 mg, 0.312 mmol), 2-bromo-3′,4′-dichloroacetophenone (167 
mg, 0.624 mmol), and LiBr (135 mg, 1.56 mmol) in THF (500 μL) was treated with Et3N (53 μL, 
0.37 mmol). SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.20 in 64% 
yield (94 mg) as a pale yellow solid: mp 132–134 °C; 1H NMR (400 MHz, CDCl3) δ 8.60 (s, 1H), 
7.98 (dd, J = 12.0, 8.4 Hz, 2H), 7.88 (d, J = 9.3 Hz, 2H), 7.70 (d, J = 2.2 Hz, 1H), 7.66 (t, J = 7.5 
Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.40 (dd, J = 8.5, 1.1 Hz, 1H), 4.18 (dd, 
J = 38, 11.3 Hz, 2H), 3.64 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 190.0 (dd, JCF = 29.9, 27.7 Hz, 
1C), 136.9, 136.1, 133.6 (dd, JCF = 5.8, 4.0 Hz, 1C), 133.4, 132.9, 132.1, 130.3, 130.2, 130.1, 
129.7, 129.3, 128.4, 127.7, 127.1, 126.2, 124.9 (t, JCF = 2.1 Hz, 1C), 115.8 (dd, JCF = 65.6, 62.4 
Hz, 1C), 77.7 (t, JCF = 25.0 Hz, 1C), 37.1 (t, JCF = 3.3 Hz, 1C); 
19F NMR (376 MHz, CDCl3) δ –
105.3 (d, JFF = 277.6 Hz, 1F), –106.9 (d, JFF = 277.7 Hz, 1F); IR (film) νmax 3519, 3061, 2924, 
1685, 1626, 1471, 1107, 749 cm–1; HRMS (ESI) m/z calcd for C20H13BrCl2F2O2 (M+H)
+ 472.9517, 
found 472.9539. 
 
4-bromo-3-(3-bromophenyl)-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)butan-1-one 3.21. 
See representative reaction procedure. . A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
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(naphthalen-2-yl)-butan-1-one (100 mg, 0.312 mmol), ), 2,3′-dibromoacetophenone (260 mg, 
0.936 mmol), and LiBr (135 mg, 1.56 mmol) in THF (500 μL) was treated with Et3N (53 μL, 0.37 
mmol). SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.21 in 71% yield 
(128 mg) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 8.60 (s, 1H), 7.99 (dd, J = 11.8, 8.4 Hz, 
2H), 7.89 (d, J = 8.5 Hz, 2H), 7.79 (s, 1H), 7.66 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.59 (ddd, J = 8.1, 
6.8, 1.2 Hz, 1H), 7.55–7.49 (m, 2H), 7.29 (t, J = 7.9 Hz, 1H), (dd, J = 26.5, 11.2 Hz , 2H), 3.63 (s, 
1H); 13C NMR (100 MHz, CDCl3) δ 190.3 (dd, JCF = 30.2, 27.5 Hz, 1C), 139.0, 136.1, 133.7 (dd, 
JCF = 6.1, 3.7 Hz, 1C), 132.2, 132.2, 130.4, 130.3, 130.0, 129.7, 128.4, 127.9, 127.2, 125.6, 125.1, 
122.9, 116.1 (dd, JCF = 267.2, 263.9 Hz, 1C),  78.0 (t, JCF = 25.0 Hz, 1C), 37.6 (t, JCF = 3.6 Hz, 
1C); 19F NMR (376 MHz, CDCl3) δ –105.6 (d, JFF = 274.7 Hz, 1F), –107.0 (d, JFF = 274.7 Hz, 
1F); IR (film) νmax 3512, 3062, 2925, 1682, 1625, 1076 cm–1; HRMS (ESI) m/z calcd for 
C20H14Br2F2O2 (M+H)
+ 482.9401, found 482.9433 
 
4-bromo-3-(4-chlorophenyl)-2,2-difluoro-3-hydroxy-1-(thiophen-2-yl)butan-1-one 3.22. See 
representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(thiophen-
2-yl)butan-1-one (100 mg, 0.363 mmol), 2-bromo-4′-chloroacetophenone (170 mg, 0.727 mmol), 
and LiBr (156 mg, 1.82 mmol) in THF (500 μL) was treated with Et3N (61 μL, 0.44 mmol). SiO2 
flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.22 in 84% yield (121 mg) as 
colorless solid: mp 97–99 °C; 1H NMR (400 MHz, CDCl3) δ 7.91 (dd, J = 3.3, 1.5 Hz, 1H), 7.79 
(d, J = 4.9 Hz, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.41–7.32 (m, 2H), 7.14 (t, J = 4.5 Hz, 1H), 4.16 (dd, 
J = 14.5, 11.3 Hz, 2H), 3.52 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 182.5 (dd, JCF = 30.9, 28.9 
Hz, 1C), 139.1 (dd, JCF = 2.7, 0.8 Hz, 1C), 137.3, 137.0 (dd, JCF = 7.0, 4.5 Hz, 1C), 135.1, 134.8, 
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128.8, 128.6 (2C), 128.4 (2C), 115.5 (q, JCF = 266.5, 263.6 Hz, 1C), 77.7 (t, JCF = 24.9 Hz, 1C), 
37.2 (t, JCF = 3.2 Hz, 1C);
19F NMR (376 MHz, CDCl3) δ –108.6 (d, JFF = 266.7 Hz, 1F), –109.7 
(d, JFF = 266.6 Hz, 1F); IR (film) νmax 3501, 3108, 1659, 1409, 1058, 728 cm–1; HRMS (ESI) m/z 
calcd for C14H10BrCl2F2O2S (M+Cl)
– 428.8930, found 428.8904. 
 
1-(benzo[d][1,3]dioxol-5-yl)-4-bromo-3-(3-bromophenyl)-2,2-difluoro-3-hydroxybutan-1-
one 3.23. See representative reaction procedure. A solution of 1-(benzo[d][1,3]dioxol-5-yl)-
2,2,4,4,4-pentafluoro-3,3-dihydroxybutan-1-one (100 mg, 0.318 mmol), 2,3′-
dibromoacetophenone (177 mg, 0.637 mmol), and LiBr (138 mg, 1.59 mmol) in THF (500 μL) 
was treated with Et3N (53 μL, 0.38 mmol). SiO2 flash chromatography (9:1 hexanes/EtOAc) 
afforded the product 3.23 in 91% yield (139 mg) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 
7.76–7.67 (m, 2H), 7.51 (ddd, J = 7.9, 1.9, 1.0 Hz, 1H), 7.49–7.44 (m, 2H), 7.28 (t, J = 7.9 Hz, 
1H), 6.85 (d, J = 8.4 Hz, 1H), 6.07 (s, 2H), 4.18–4.08 (m, 2H), 3.62 (d, J = 0.9 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 188.2 (dd, JCF = 30.3, 27.6 Hz, 1C), 153.4, 148.1, 139.0, 132.1, 130.3, 129.9, 
128.3 (dd, JCF = 5.7, 3.6 Hz, 1C), 127.5–127.4 (m, 1C), 125.6, 122.8, 115.9 (dd, JCF = 267.5, 263.5 
Hz, 1C), 110.2 (dd, JCF = 4.3, 2.5 Hz, 1C), 108.2, 102.3, 77.9 (t, JCF = 25.5, 24.4 Hz, 1C), 37.5 (t, 
JCF = 3.5 Hz, 1C); 
19F NMR (376 MHz, CDCl3) δ –105.2 (d, JFF = 275.8 Hz, 1F), –106.7 (d, JFF = 
275.9 Hz, 1F); IR (film) νmax 3507, 3079, 2910, 1680, 1605, 1445, 1268, 1089, 797 cm–1; HRMS 
(ESI) m/z calcd for C17H12ClBr2F2O4 (M+Cl)
– 510.8759, found 510.8751. 
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1-((3r,5r,7r)-adamantan-1-yl)-4-bromo-3-(4-chlorophenyl)-2,2-difluoro-3-hydroxybutan-1-
one 3.24. See representative reaction procedure. A solution of 1-((3r,5r,7r)-adamantan-1-yl)-
2,2,4,4,4-pentafluoro-3,3-dihydroxybutan-1-one (300 mg, 0.914 mmol), 2-bromo-4′-
chloroacetophenone (427 mg, 1.83 mmol), and LiBr (397 mg, 4.57 mmol) in THF (2 mL) was 
treated with Et3N (153 μL, 1.10 mmol). SiO2 flash chromatography (19:2:1 
hexanes/dichloromethane/EtOAc) afforded the product 3.24 in 57% yield (236 mg) as a colorless 
solid: mp 106–108 °C; 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 8.5 Hz, 2H), 7.37 (d, J = 8.7 Hz, 
2H), 4.16–3.99 (m, 3H), 2.00 (s, 3H), 1.79 (t, J = 20.7, 13.5 Hz, 6H), 1.68 (dd, J = 34.4, 13.0 Hz, 
6H); 13C NMR (100 MHz, CDCl3) δ 206.3 (dd, JCF = 30.0, 25.3 Hz, 1C), 135.6, 135.0, 128.6 (2C), 
128.5 (2C), 115.4 (dd, JCF = 271.4, 267.1 Hz, 1C), 78.4 (t, JCF = 23.9 Hz), 47.6 (d, JCF = 2.1 Hz), 
37.1 (d, JCF = 3.8 Hz, 1C), 36.8 (d, JCF = 2.3 Hz, 3C), 36.3 (3C), 27.7 (3C); 
19F NMR (376 MHz, 
CDCl3) δ –106.3 (d, JFF = 284.2 Hz, 1F), –110.4 (d, JFF = 284.2 Hz, 1F); IR (film) νmax 3520, 2912, 
2856, 1714, 1495, 1093 cm–1; HRMS (ESI) m/z calcd for C20H22BrCl2F2O2 (M+Cl)
– 481.0148, 
found 481.0116. 
 
4-chloro-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)-3-phenylbutan-1-one 3.25. See 
representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)-butan-1-one (100 mg, 0.312 mmol), 2-chloroacetophenone (97 mg, 0.62 mmol), 
and LiCl (66 mg, 1.6 mmol) in THF (500 μL) was treated with Et3N (53 μL, 0.37 mmol). SiO2 
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flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.25 in 71% yield (80 mg) as a 
colorless film: 1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H), 7.95 (dd, J = 14.3, 8.2 Hz, 2H), 7.85 
(dd, J = 8.4, 4.5 Hz, 2H), 7.67–7.53 (m, 4H), 7.44–7.36 (m, 3H), 4.38 (s, 2H), 3.64 (s, 1H); 13C 
NMR (100 MHz, CDCl3) δ 190.59 (dd, JCF = 30.0, 27.8 Hz, 1C), 136.06, 135.99, 133.67 (dd, JCF 
= 5.5, 4.1 Hz, 1C), 132.24, 130.66, 130.36, 129.58, 129.10, 128.58, 128.30, 127.83, 127.08, 
127.06, 125.17, 118.25 (dd, JCF = 220.7 Hz, 265.9 Hz, 1C),  78.64 (t, JCF = 24.8 Hz, 1C), 48.31 (t, 
JCF = 3.9 Hz, 1C); 
19F NMR (377 MHz, CDCl3) δ –106.6 (d, JFF = 271.8 Hz, 1F), –107. 8 (d, JFF 
= 271.8 Hz, 1F); IR (film) νmax 3529, 3061, 2925, 1685, 1625, 1450, 1091, 1072, 701 cm–1; HRMS 
(ESI) m/z calcd for C20H16ClF2O2 (M+H)
+ 361.0801, found 361.0782. 
 
4-chloro-3-(4-chlorophenyl)-2,2-difluoro-3-hydroxy-1-(naphthalen-2-yl)butan-1-one 3.26. 
See representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)-butan-1-one (30 mg, 0.094 mmol), 2,4'-dichloroacetophenone (35 mg, 0.19 
mmol), and LiCl (26 mg, 0.61 mmol) in THF (500 μL) was treated with Et3N (26 μL, 0.189 mmol). 
SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.26 in 60% yield (22 mg) 
as a colorless solid: mp 107–109 °C; 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 1H), 7.97 (dd, J = 
15.3, 8.4 Hz, 2H), 7.86 (d, J = 8.6 Hz, 2H), 7.69 – 7.61 (m, 1H), 7.58 (d, J = 7.1 Hz, 1H), 7.54 (d, 
J = 8.8 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 4.37 (dd, J = 11.9, 11.9 Hz, 2H), 3.73 (s, 1H). 13C NMR 
(100 MHz, CDCl3) δ 190.20 (t, JCF = 27.9 Hz, 1C), 136.00, 135.12, 134.49, 133.60 (dd, JCF = 4.2, 
4.2 Hz, 1C), 132.10, 130.31, 130.22, 129.58, 128.62, 128.49, 128.28, 127.72, 127.03, 124.95 (t, 
JCF = 2.1 Hz, 1C), 116.8 (dd, JCF = 204.4, 201.7 Hz, 1C), 78.36 (t, JCF = 24.8 Hz, 1C), 47.95 (t, 
JCF = 3.8 Hz, 1C); 
19F NMR (377 MHz, CDCl3) δ –106.3 (d, JFF = 275.8 Hz, 1F), –107.7 (d, JFF = 
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275.6 Hz, 1F); IR (film) νmax 3513, 3060, 2925, 1682, 1671, 1624, 1495, 1089, 1009, 735 cm–1; 
HRMS (ESI) m/z calcd for C20H14Cl2F2NaO2 (M+Na)
+ 417.0231, found 417.0242. 
 
4-chloro-2,2-difluoro-3-hydroxy-3-methyl-1-(naphthalen-2-yl)butan-1-one 3.27. See 
representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)-butan-1-one (100 mg, 0.312 mmol), chloroacetone (125 µL, 1.56 mmol), and 
LiCl (66 mg, 1.6 mmol) in THF (500 μL) was treated with Et3N (53 μL, 0.37 mmol). SiO2 flash 
chromatography (19:1 hexanes/EtOAc) afforded the product 3.27 in 66% yield (68 mg) as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 8.73 (s, 1H), 8.09 (d, J = 8.3 Hz, 1H), 8.00 (d, J = 8.1 
Hz, 1H), 7.93 – 7.87 (m, 2H), 7.66 (t, J = 8.1 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 3.91 (dd, J = 85.3, 
11.7 Hz, 2H), 3.09 (s, 1H), 1.60 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 190.6 (t, JCF = 29.8 Hz, 
1C), 136.1, 133.8 (t, JCF = 4.9 Hz, 1C), 132.3, 130.3, 129.6, 128.4, 127.8, 127.1, 125.1, 117.2 (t, 
JCF = 263.3 Hz, 1C), 75.2 (t, JCF = 24.4 Hz, 1C), 48.7– 48.5 (m, 1C), 19.7; 19F NMR (376 MHz, 
CDCl3) δ –108.9 (d, JFF = 284.0 Hz, 1F), –110.6 (d, JFF = 284.0 Hz 1F); IR (film) νmax 3361, 2924, 
2853, 1686, 1662, 1625, 1494, 1109, 762, 747 cm–1; HRMS (ESI) m/z calcd for C15H14ClF2O2 
(M+H)+ 299.0645, found 299.0623. 
 
4-chloro-1-(4-chlorophenyl)-2,2-difluoro-3-hydroxy-3-methylbutan-1-one 3.28. See 
representative reaction procedure. A solution of 1-(4-chlorophenyl)-2,2,4,4,4-pentafluoro-3,3-
dihydroxybutan-1-one (65 mg, 0.21 mmol), chloroacetone (85 µL, 1.1 mmol), and LiCl (45 mg, 
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1.1 mmol) in THF (500 μL) was treated with Et3N (36 μL, 0.26 mmol). SiO2 flash chromatography 
(19:1 hexanes/EtOAc) afforded the product 3.28 in 46% yield (30 mg) as a colorless oil: 1H NMR 
(400 MHz, CDCl3) δ 8.06 (d, J = 8.6 Hz, 2H), 7.47 (d, J = 8.7 Hz, 2H), 3.85 (dd, J = 83.4, 11.7 
Hz, 2H), 2.92 (s, 1H), 1.55 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 188.7 (t, JCF = 30.3 Hz, 1C), 
140.5, 131.2 (t, JCF = 3.7 Hz, 2C), 130.5 (t, JCF = 2.0 Hz, 1C), 128.1 (2C), 122.6–112.1 (m, 1C), 
74.1 (t, JCF = 24.7 Hz, 1C), 47.6 (dd, JCF = 4.6, 3.2 Hz, 1C), 18.8 (dd, JCF = 3.8, 2.3 Hz, 1C);
 19F 
NMR (376 MHz, CDCl3) δ –109.7 (d, JFF = 281.0 Hz, 1F), –111.4 (d, JFF = 281.1 Hz, 1F); IR 
(film) νmax 3509, 2929, 2860, 1695, 1589, 1090 cm–1; HRMS (ESI) m/z calcd for C11H11Cl2F2O2 
(M+H)+ 283.0099, found 283.0095. 
 
4-chloro-3-(4-chlorophenyl)-2,2-difluoro-3-hydroxy-1-(thiophen-2-yl)butan-1-one 3.29. See 
representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(thiophen-
2-yl)butan-1-one (55 mg, 0.20 mmol), 2,4'-dichloroacetophenone (76 mg, 0.04 mmol), and LiCl 
(42 mg, 1.0 mmol) in THF (500 μL) was treated with Et3N (33 μL, 0.24 mmol). SiO2 flash 
chromatography (19:1 hexanes/EtOAc) afforded the product 3.29 in 77% yield (54 mg) as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.95–7.91 (m, 1H), 7.79 (dd, J = 4.9, 1.0 Hz, 1H), 
7.49 (d, J = 8.5 Hz, 2H), 7.39–7.35 (m, 2H), 7.15 (dd, J = 4.8, 4.1 Hz, 1H), 4.33–4.24 (m, 2H), 
3.55 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 182.7 (t, JCF = 29.9 Hz, 1C), 139.3, 137.4, 137.1 (dd, 
JCF = 6.6, 5.2 Hz, 1C), 135.3, 134.4, 128.9, 128.8 (2C), 128.6 (2C), 116.1 (t, JCF = 267.5 Hz, 1C), 
78.3 (t, JCF = 24.7 Hz, 1C), 47.9 (t, JCF = 3.6 Hz, 1C);
19F NMR (376 MHz, CDCl3) δ –109.0 (d, 
JFF = 268.6 Hz, 1F), –110.0 (d, JFF = 268.6 Hz, 1F); IR (film) νmax 3493, 3115, 2926, 1666, 1414, 
1095, 733 cm–1; HRMS (ESI) m/z calcd for C14H11Cl2F2O2S (M+H)
+ 350.9819, found 350.9849. 
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1-(benzo[d][1,3]dioxol-5-yl)-4-chloro-2,2-difluoro-3-hydroxy-3-phenylbutan-1-one 3.30. See 
representative reaction procedure. A solution of 1-(benzo[d][1,3]dioxol-5-yl)-2,2,4,4,4-
pentafluoro-3,3-dihydroxybutan-1-one (100 mg, 0.318 mmol), 2-chloroacetophenone (98 mg, 0.64 
mmol), and LiCl (67 mg, 1.6 mmol) in THF (500 μL) was treated with Et3N (53 μL, 0.38 mmol). 
SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.30 in 95% yield (107 
mg) as a colorless oil: 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 7.1 Hz, 
2H), 7.45 (s, 1H), 7.44–7.35 (m, 3H), 6.82 (d, J = 8.4 Hz, 1H), 6.05 (s, 2H), 4.31 (dd, J = 16.6, 
11.6 Hz, 2H), 3.63 (s, 1H); 13C NMR (126 MHz, CDCl3) δ 188.5 (dd, JCF = 29.5, 27.3 Hz, 1C), 
153.1, 148.0, 136.0, 129.0, 128.5 (2C), 128.2 (dd, JCF = 5.4, 3.7 Hz, 1C), 127.7, 127.0 (2C), 116.7 
(dd, JCF = 265.9, 263.2 Hz, 1C), 110.2 (dd, JCF = 4.1, 2.8 Hz, 1C), 108.1, 102.2, 78.5 (t, JCF = 24.8 
Hz, 1C), 48.2 (t, JCF = 4.1 Hz, 1C); 
19F NMR (376 MHz, CDCl3) δ –106.3 (d, JFF = 272.1 Hz, 1F), 
–107.6 (d, JFF = 272.1 Hz, 1F); IR (film) νmax 3504, 2911, 1680, 1604, 1444, 1268, 1034, 701 cm–
1; HRMS (ESI) m/z calcd for C17H13Cl2F2O4 (M+Cl)
– 389.0159, found 389.0162. 
 
1-((3r,5r,7r)-adamantan-1-yl)-4-chloro-2,2-difluoro-3-hydroxy-3-phenylbutan-1-one 3.21. 
See representative reaction procedure. A solution of 1-((3r,5r,7r)-adamantan-1-yl)-2,2,4,4,4-
pentafluoro-3,3-dihydroxybutan-1-one (100 mg, 0.304 mmol), 2-chloroacetophenone (94 mg, 0.61 
mmol), and LiCl (65 mg, 1.5 mmol) in THF (500 μL) was treated with Et3N (51 μL, 0.37 mmol). 
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SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.21 in 51% yield (57 mg) 
as a colorless solid: 102–103 mp °C;  1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.5 Hz, 2H), 
7.43–7.33 (m, 3H), 4.24 (dd, J = 28.4, 11.7 Hz, 2H), 4.08 (s, 1H), 1.98 (s, 3H), 1.83–1.74 (m, 6H), 
1.73–1.58 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 206.5 (dd, JCF = 29.2, 24.3 Hz, 1C), 136.3, 
128.9, 128.5 (2C), 127.1 (2C), 119.1–113.1 (m, 1C), 77.0 (t, JCF = 23.7 Hz, 1C), 48.0 (t, JCF = 4.1 
Hz, 1C), 36.7 (d, JCF = 2.2 Hz, 3C), 36.4 (3C), 27.7 (3C);
 19F NMR (376 MHz, CDCl3) δ –106.7 
(d, JFF = 282.3 Hz, 1F), –111.2 (d, JFF = 282.0 Hz, 1F); IR (film) νmax 3506, 2912, 2856, 1716, 
1452, 1075, 773 cm–1; HRMS (ESI) m/z calcd for C20H23ClF2NaO2 (M+Na)
+ 391.1252, found 
391.1230. 
 
1-chloro-2-(4-chlorophenyl)-3,3-difluoro-2-hydroxy-6-methylheptan-4-one 3.22. See 
representative reaction procedure. A solution of 1,1,1,3,3-pentafluoro-2,2-dihydroxy-6-
methylheptan-4-one (75 mg, 0.30 mmol), 2,4'-dichloroacetophenone (108 mg, 0.598 mmol), and 
LiCl (63 mg, 1.5 mmol) in THF (500 μL) was treated with Et3N (50 μL, 0.36 mmol). SiO2 flash 
chromatography (19:1 hexanes/EtOAc) afforded the product 3.22 in 80% yield (70 mg) as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.6 Hz, 2H), 
4.17 (dd, J = 34.2, 12.0 Hz, 2H), 3.14 (s, 1H), 2.58–2.41 (m, 2H), 2.18–2.03 (m, 1H), 0.87 (dd, J 
= 6.4, 2.6 Hz, 9H); 13C NMR (100 MHz, CDCl3) δ 201.1 (t, JCF = 29.1, 28.0 Hz, 1C), 135.3, 134.3, 
128.8 (2C), 128.3 (2C), 114.7 (t, JCF = 264.1 Hz, 1C), 78.1 (t, JCF = 24.9 Hz, 1C), 48.0 (t, JCF = 
3.8 Hz, 1C), 47.7, 23.5, 22.4, 22.4; 19F NMR (376 MHz, CDCl3) δ –115.1 (d, JFF = 263.0 Hz, 1F), 
–115.9 (d, JFF = 262.6 Hz, 1F); IR (film) νmax 3514, 2965, 2930, 1741, 1496, 1097, 372 cm–1; 
HRMS (ESI) m/z calcd for C14H16Cl3F2O2 (M+Cl)
– 359.0184, found 359.0205. 
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1-(4-chlorophenyl)-2,2-difluoro-2-(2-(4-methoxyphenyl)oxiran-2-yl)ethan-1-one 3.35. See 
representative reaction procedure. A solution of 1-(4-chlorophenyl)-2,2,4,4,4-pentafluoro-3,3-
dihydroxybutan-1-one (75 mg, 0.25 mmol), 2-bromo-4′-methoxyacetophenone (65 mg, 0.49 
mmol), and LiBr (107 mg, 1.23 mmol) in THF (500 μL) was treated with Et3N (41 μL, 0.30 mmol). 
SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.35 in 58% yield (48 mg) 
as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.7 Hz, 2H), 
7.39 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 3.79 (s, 2H), 3.42 (d, J = 5.2 Hz, 1H), 2.93 (d, 
J = 3.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 187.5 (t, JCF = 28.9 Hz, 1C), 160.3, 141.2, 131.8 
(t, JCF = 3.1 Hz, 2C), 131.1, 129.3 (2C), 129.1 (2C), 124.1, 116.6 (dd, JCF = 261.0, 257.6 Hz, 1C), 
114.0 (2C), 59.1 (dd, JCF = 32.0, 28.9 Hz, 1C), 55.4, 51.2 (dd, JCF = 3.9, 2.6 Hz, 1C); 
19F NMR 
(376 MHz, CDCl3) δ –104.88 (d, JFF = 270.8 Hz, 1F), –107.50 (d, JFF = 270.8 Hz, 1F); IR (film) 
νmax 3418, 2965, 2844, 1675, 1601, 1256, 1093 cm–1; HRMS (ESI) m/z calcd for C17H14ClF2O3 
(M+H)+ 339.0594, found 339.0603. 
 
2,2-difluoro-2-(2-(4-methoxyphenyl)oxiran-2-yl)-1-(naphthalen-2-yl)ethan-1-one 3.36. See 
representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)butan-1-one 3.17 (200 mg, 0.624 mmol), 2-bromo-4′-methoxyacetophenone 3.34 
(347 mg, 1.25 mmol), and LiBr (270 mg, 3.12 mmol) in THF (500 μL) was treated with Et3N (104 
μL, 0.749 mmol). SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.36 in 
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46% yield (101 mg) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 8.65 (s, 1H), 8.00 (t, J = 9.2 
Hz, 2H), 7.91–7.83 (m, 2H), 7.64 (t, J = 7.6 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 7.45 (dd, J = 8.6, 
1.6 Hz, 2H), 6.87 (dd, J = 8.9, 2.1 Hz, 2H), 3.78 (d, J = 2.2 Hz, 2H), 3.52 (dd, J = 5.3, 2.1 Hz, 1H), 
3.00–2.96 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 188.4 (t, JCF = 28.6 Hz, 1C), 160.3, 136.1, 
133.3 (t, JCF = 4.0 Hz, 1C), 132.3, 130.3, 130.0, 129.5, 129.4 (2C), 128.5, 127.8, 127.1, 124.9, 
124.4, 116.8 (dd, JCF = 260.7, 256.9 Hz, 1C), 113.9 (2C), 59.3 (dd, JCF = 32.0, 28.6 Hz, 1C), 55.4, 
51.3 (dd, JCF = 3.9, 2.6 Hz, 1C); 
19F NMR (376 MHz, CDCl3) δ –104.61 (d, JFF = 270.4 Hz, 1F), 
–107.18 (d, JFF = 270.3 Hz, 1F); IR (film) νmax 3062, 2934, 1697, 1516, 1250, 1120 cm–1; HRMS 
(ESI) m/z calcd for C21H17F2O3 (M+H)
+ 355.1140, found 355.1147. 
 
 
 
 
1-((3r,5r,7r)-adamantan-1-yl)-3-(4-chlorophenyl)-2,2-difluoro-3-hydroxybutan-1-one 3.37. 
To a solution of bromohydrin 3.24 (25 mg, 0.056 mmol) in THF (1 ml), Et3N (23 µL, 0.17 mmol) 
was added dropwise. The reaction was stirred for 24 hours at rt. The mixture was quenched with 
saturated aqueous NH4Cl (1 mL) and extracted with CH2Cl2 (3 × 3 mL). The organics were dried 
over Na2SO4 and concentrated under reduced pressure. SiO2 flash chromatography (4:1 hexanes/ 
CH2Cl2) afforded the product 3.37 in 29% yield (6 mg) as a solid: mp 88-90 °C;
 1H NMR (400 
MHz, CDCl3) δ 7.41 (d, J = 8.5 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 3.32 (d, J = 5.2 Hz, 1H), 2.82 
(dt, J = 4.4, 1.7 Hz, 1H), 2.01 (s, 1H), 1.95–1.76 (m, 6H), 1.69 (q, J = 12.4 Hz, 6H);  13C NMR 
(100 MHz, CDCl3) δ 203.0 (t, JCF = 26.6 Hz, 1C), 135.2, 131.5, 129.6 (2C), 128.7 (2C), 116.8 (t, 
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JCF = 261.8 Hz, 1C), 59.2 (t, JCF = 29.7 Hz, 1C), 50.7 (t, JCF = 3.7 Hz, 1C), 46.7 (t, JCF = 2.1 Hz, 
1C), 36.9 (3C), 36.4 (3C), 27.7 (3C); 19F NMR (376 MHz, CDCl3) δ –107.0 (s, 2F); IR (film) νmax 
3501, 2912, 2856, 1706, 1454, 1093 cm–1; HRMS (ESI) m/z calcd for C20H23Cl2F2O2 (M+Cl)
– 
403.1043, found 403.1070. 
 
2-(2-chloro-1-hydroxycyclohexyl)-2,2-difluoro-1-(naphthalen-2-yl)ethan-1-one 3.41. See 
representative reaction procedure. A solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalen-2-yl)butan-1-one 3.17 (100 mg, 0.312 mmol), chlorocyclohexanone 3.40 (178 µL, 
1.56 mmol), and LiCl (66 mg, 1.6 mmol) in THF (500 μL) was treated with Et3N (53 μL, 0.37 
mmol). SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.41 in 67% yield 
(106 mg) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.07 (d, J = 8.9 Hz, 1H), 
8.00 (d, J = 8.2 Hz, 1H), 7.89 (t, J = 8.4 Hz, 2H), 7.64 (t, J = 7.0 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 
4.45 (dd, J = 10.9, 5.2 Hz, 1H), 3.60 (d, J = 2.1 Hz, 1H), 2.14 (d, J = 13.9 Hz, 1H), 2.10– 1.98 (m, 
2H), 1.76 (t, J = 15.4 Hz, 2H), 1.70–1.59 (m, 2H), 1.41 (d, J = 16.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 191.6 (dd, JCF = 30.7, 28.7 Hz, 1C), 136.0, 133.4 (dd, JCF = 6.3, 4.0 Hz, 1C), 132.4, 
131.1, 130.3, 129.5, 128.5, 127.9, 127.1, 125.5–125.4 (m, 1C), 117.0 (dd, JCF = 264.8, 261.9 Hz, 
1C), 76.7 (t, JCF = 23.6 Hz, 1C), 33.1, 31.3 (dd, JCF = 2.8, 2.9 Hz, 1C), 29.9–29.8 (m, 1C), 19.7; 
19F NMR (377 MHz, CDCl3) δ –108.7 (d, JFF = 279.0 Hz, 1F), –110.5 (d, JFF = 278.8 Hz, 1F); IR 
(film) νmax 2474, 2944, 2867, 1720, 1626, 1449, 1114, 758 cm–1; HRMS (ESI) m/z calcd for 
C18H17Cl2NaO2 (M+Na)
+ 361.0777, found 361.0764. 
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1-((3r,5r,7r)-adamantan-1-yl)-2-(2-(4-chlorophenyl)oxiran-2-yl)-2,2-difluoroethan-1-one 
3.42. A solution of bromohydrin 3.24 (50 mg, 0.11 mmol) and Bu3SnH (36 µL, 0.134 mmol) in 
toluene (5 ml) was heated to 110 °C, then AIBN (1 mg, 0.06 mmol) was added and the reaction 
was stirred for 16 hours. The mixture was concentrated under reduced pressure. SiO2 flash 
chromatography (19:1 hexanes/EtOAc) afforded the product 3.42 in 41% yield (17 mg) as a solid: 
mp 98–100 °C; 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.7 Hz, 1H), 
4.34 (s, 1H), 1.99 (s, 3H), 1.86–1.68 (m, 9H), 1.67–1.61 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 
207.8 (dd, JCF = 30.7, 27.5 Hz, 1C), 139.1 (d, JCF = 2.6 Hz, 1C), 134.0, 128.2 (2C), 127.9 (2C), 
115.5 (t, JCF = 267.4 Hz, 1C), 76.5 (t, JCF = 24.2 Hz, 1C), 36.7 (3C),  36.2 (3C),  29.7, 27.5 (3C), 
23.5 (dd, JCF = 3.7, 2.4 Hz, 1C);
 19F NMR (376 MHz, CDCl3) δ –108.79 (d, JFF = 293.6 Hz, 1F), 
–112.87 (d, JFF = 294.5 Hz, 1F); IR (film) νmax 2912, 2853, 1720, 1498, 1092 cm–1; HRMS (ESI) 
m/z calcd for C20H21ClF2NaO2 (M+Na)
+ 389.1096, found 389.1090. 
 
2,2-difluoro-2-(2-methyl-5-phenyl-4,5-dihydrooxazol-5-yl)-1-(naphthalen-2-yl)ethan-1-one 
28. To a solution of bromohydrin 3.19 (140 mg, 0.388 mmol) and CsF (314 mg, 1.94 mmol) in 
CH3CN (5 ml), BF3.Et2O (239 µL, 1.94 mmol) was added dropwise. The reaction was stirred for 
16 hours at 80 °C. The mixture was quenched with saturated aqueous NH4Cl (5 mL) and extracted 
with CH2Cl2 (3 × 5 mL). The organics were dried over Na2SO4 and concentrated under reduced 
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pressure. SiO2 flash chromatography (19:1 hexanes/EtOAc) afforded the product 3.43 in 42% yield 
(60 mg) as a pale yellow oil: 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 7.96–7.76 (m, 4H), 7.60 
(t, J = 7.7 Hz, 1H), 7.52 (d, J = 7.0 Hz, 3H), 7.37–7.27 (m, 3H), 5.24 (d, J = 9.3 Hz, 1H), 4.57 (d, 
J = 9.3 Hz, 1H), 2.03 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 190.3 (t, JCF = 29.1 Hz, 1C), 168.0, 
139.1, 135.9, 133.6 (t, JCF = 4.9 Hz, 1C), 132.2, 130.9, 130.3, 129.3, 128.6, 128.5 (2C), 128.1, 
128.0 (2C), 127.8, 126.9, 125.3, 117.9 (t, JCF = 262.8 Hz, 1C), 80.4 (t, JCF = 23.0 Hz, 1C), 74.7 (t, 
JCF = 3.6 Hz, 1C), 14.1;
 19F NMR (376 MHz, CDCl3) δ –107.27 (d, JFF = 264.4 Hz, 1F), –109.16 
(d, JFF = 264.8 Hz, 1F); IR (film) νmax 3318, 2924, 1663, 1275, 1112, 749 cm–1; HRMS (ESI) m/z 
calcd for C22H26F2NaO2 (M+Na)
+ 383.1793, found 383.1796. 
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CHAPTER 4 
FLUORINATED BIOLOGICAL TAGS 
4.1. Fluorinated Antibody-Drug Conjugates 
Despite the large strides in cancer research, treating cancer remains one of the major 
challenges facing mankind. Cancer is among the leading causes of death worldwide; it’s 
responsible for 1 in 6 deaths globally.177 Approximately 40% of people will be diagnosed with 
cancer during their lifetime. Efforts to treat cancer are often limited by the high toxicity of the 
small molecules used in chemotherapy. One approach to address this issue is through the use of 
antibody-drug conjugates (ADCs). These conjugates are comprised of a highly cytotoxic agent 
linked to an antibody that preferentially target cancer cells. ADCs utilize the targetability of 
antibodies in delivering the anticancer drug selectively to the cancerous cells; thus, reducing the 
dose-limiting toxicities while at the same time increasing the therapeutic effect. The concept of 
ADCs can also be employed in other diseases.  
In 2000, Mylotarg was granted expedited approval by the FDA to become the first ADC to 
enter the market.179 It was marketed for the treatment of acute myeloid leukemia and remained the 
only ADC on the market until 2010 when it was voluntarily withdrawn due to concerns about 
safety and clinical benefits. In 2017, Mylotarg was reapproved by the FDA for the same indication 
but with a new dosing regimen.  
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The second and third ADCs to be approved by the FDA were Adcetris in 2011 and Kadcyla 
in 2013. Adcetris is used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma, 
and Kadcyla for the treatment of HER2-positive breast cancer.179 The latest addition to the list of 
marketed ADCs came in 2017, when Besponsa was approved for the treatment of relapsed or 
refractory B-cell precursor acute lymphoblastic leukemia.  
Linkers are an important part of the ADC structure, they connect the drug to the carrier 
antibody (Figure 4.1). ADC linkers can be cleavable or non-cleavable under physiological 
conditions. ADCs containing non-cleavable linkers release the drug through the degradation of the 
antibody following its internalization into the cancer cell.  These linkers provide higher stability 
in plasma, but their efficacy might be restricted by the limitations of the “bystander” effect.182 On 
the other hand, cleavable linkers release the drug by chemical or enzymatic degradation of the 
linker.183 The chemically labile linkers usually contain a hydrazone functional group or a disulfide 
group. The hydrazine group is hydrolyzed at the acidic pH found in the lysosomal and endosomal 
compartments of the tumor tissue while being stable in the slightly basic plasma and cytosol, and 
the disulfide-based linkers release the drug upon reduction by glutathione. On the other hand, the 
enzymatically cleavable linkers contain a dipeptide moiety,  typically a valine-citrulline dipeptide, 
that is susceptible to hydrolysis by proteases in the tumor cells.184 
 
 
 
 
 
Figure 4.1. Antibody-drug conjugates structure 
Antibody 
Linker Drug Fluorinated 
linker 
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ADCs realize Paul Ehrlich's theory of the “magic bullet” drug. They deliver the drug with 
high specificity to the site of action, reducing the possible side effects of highly toxic therapeutic 
agents in many anticancer treatments. With several ADCs on the market and over 60 ADCs in 
clinical trials, means to monitor their efficiency, strength and quality become necessary. This is 
especially important since most ADCs are generated through non-specific conjugation between 
the drug and the antibody. This non-specific conjugation results in heterogeneous mixtures where 
one antibody can carry a variable number of drug molecules. The different ADC species in this 
heterogeneous mixture have different physico-chemical properties, and as a result, different 
efficacies. 
The chemistry of ADC linkers has been gaining a lot of interest recently. The successful 
and selective cleavage of the linker is essential for the function of ADCs. In addition to their 
traditional role, linkers can provide a handle for tagging ADCs. The incorporation of fluorine into 
linkers minimally affect the sterics of the linker owing to the small size of fluorine atom, while at 
the same time providing an observable tag. Fluorinated ADC linkers provide a means to validate 
the stability of the ADC in circulation in vivo and the effective degradation at the site of action. 
Fluorinated linkers allow the facile evaluation of the stability of ADCs in formulation as well as 
the rate of release of the drug from the conjugate. Methods like 19F NMR and PET scans can be 
integrated in this approach. 
19F nucleus occurs at 100% natural abundance; which accounts for the high sensitivity of 
19F NMR. 19F NMR spectra are well resolved with a chemical shift range that is 100-fold larger 
than that of 1H. Due to the great sensitivity of the chemical shifts in 19F NMR to the local 
electrostatic field, minor changes in the structure of the molecule can be easily detected in the 19F 
NMR spectra. These characteristics distinguish 19F NMR as a valuable analytical tool.  19F NMR 
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is ideal for studying fluorinated molecules in vitro and in vivo without any interfering background 
signal, since 19F does not occur naturally in biological systems.185 We aim to monitor drug release 
from ADC using 19F NMR. As the linker is being hydrolyzed, the peak for the ADC bound linker 
will start to disappear and that of the free linker will start to be observed. By using the integration 
of the peaks in reference to the integration of the internal standard (trifluorotoluene) we can 
quantitatively measure the release of the drug over time.  
 
4.1.1. Design and Synthesis of Fluorinated Antibody-Drug Conjugates 
 This linker is comprised of a maleimidocaproyl (mc) group linking the antibody to the 
enzymatically cleavable valine-citrulline (vc) moiety, which in turn is linked to the drug through 
a p-aminobenzyl alcohol (PABA) spacer (Figure 4.2-a). The linker is modified to contain fluorine 
at both sides of the linker; at the antibody side and the drug side. Two fluorine atoms are introduced 
on the mc group to monitor the release of the antibody and a trifluoromethyl (CF3) group is 
introduced on the PABA group to monitor the release of the drug (Figure 4.2-b). Furthermore, for 
the initial studies we opted to use 5-fluorouracil, a fluorinated chemotherapeutic agent, to allow 
tracking of the drug itself using 19F NMR.  
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Figure 4.2. The structures of: a) the Adcetris linker and, b) its fluorinated analogue  
 
4.1.2. First Approach Towards Synthesis of Fluorinated Antibody-Drug Conjugates 
Our retrosynthetic analysis started with disconnecting the drug from the linker. This was 
followed by disconnecting the mc group, then the PABA group. Finally, the dipeptide was 
disconnected to the commercially available amino acids (Scheme 4.1). 
 
 
 
 
 
 
 
 
Scheme 4.1. Retrosynthetic analysis of the fluorinated linker 
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The synthesis of the linker commenced with the construction of the mc group. A copper-
mediated coupling reaction between ethyl bromodifluoroacetate (4.7) and acrylonitrile 
(4.8) afforded compound 4.9 in 87% yield (Scheme 4.2).186 Next, we attempted to reduce the 
nitrile group to the corresponding amine (4.10). Using palladium catalyzed hydrogenation under 
acidic conditions successfully reduced the nitrile but unfortunately the product proceeded to 
cyclize to give rise to the lactam (4.11). Carrying the same transformation under neutral conditions 
resulted in cyclization as well. To reduce the unwanted cyclization, we reduced the ester in 
compound 4.10 to the corresponding carboxylic acid 4.12 then attempted the hydrogenation 
reaction, but yet again the major product was the lactam 4.11. Since we haven’t been able to avoid 
the formation of compound 4.11, we tried next to hydrolyze it to the uncyclized form, but this 
resulted in a mixture of 2 inseparable products. In view of the difficulty we faced in accessing the 
amine, we decided to move forward with compound 4.12.  
 
 
 
 
 
 
 
 
 
Scheme 4.2. Synthesis of the mc group 
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Next, we proceeded to couple the boc-protected valine 4.5 with citrulline (4.6) to make the 
vc dipeptide 4.4 (Scheme 4.3). this reaction proceeded in 81% yield, and no epimerization was 
observed. On the other hand, the fluorinated PABA group was synthesized by reducing 4-amino-
3-(trifluoromethyl)benzoic acid (4.14) to the alcohol 4.15, which was then protected with a tert-
butyldimethylsilyl group to give rise to compound 4.16 (Scheme 4.4). 
 
 
 
Scheme 4.3. Synthesis of the vc dipeptide 
 
 
 
 
Scheme 4.4. Synthesis of the protected trifluoromethylated PABA group 
 
Once we had compounds 4.4 and 4.16 on hand we attempted amide coupling reaction to 
access compound 4.17 (Scheme 4.5). We first attempted to use N-ethoxycarbonyl-2-ethoxy-1,2-
dihydroquinoline (EDQQ) as a coupling reagent and Hünig's base in CH2Cl2/MeOH for 24 h, these 
conditions failed to produce the desired product. Next, we tried HATU as a coupling reagent but 
again we were not successful in generating compound 4.17. Increasing reaction time to 72 as well 
as using DMF as solvent didn’t help. Next, we screened other coupling reagents, including 
DCC/HOBt, EDC/HOBt and DIC/HOBt but none of them provided the desired product. 
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Scheme 4.5. Attempted coupling of trifluoromethylated PABA to the vc dipeptide 
 
We believed that the steric hindrance of the CF3 group and its proximity to the reaction site 
could have prevented the successful coupling of PABA to the vc peptide. To address this issue, we 
decided to use one fluorine atom instead of the CF3 group and to place it at the meta position. The 
reduction of 4-amino-2-fluorobenzoic acid (4.18) using LiAlH4 followed by protection of the 
alcohol using TBDPSCl afforded the protected monofluorinated PABA (4.20) (Scheme 4.6).  
  
 
 
Scheme 4.6. Synthesis of the protected monofluorinated PABA group 
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Once we had compound 4.20, we tried to couple it to the vc dipeptide 4.4. Neither using 
HATU coupling reagent nor using N-hydroxysuccinimide (HOSu) provided the desired coupling 
product (Scheme 4.7). Fortunately, using DCC under acidic conditions provided the coupled 
product but at the same time removed the Boc protecting group. This transformation accomplished 
two steps in one pot, and with compound 4.21 in hand we could move forward with the synthesis. 
 
 
 
 
 
 
 
 
Scheme 4.7. Coupling of monofluorinated PABA to the vc dipeptide 
The next step in the synthesis is to couple compound 4.21 to the fluorinated mc analogue 
4.12 (Scheme 4.8).  The conditions screened for this step were, HATU with Hünig's base, DCC 
under acidic conditions, and DCC with HOSu. None of these conditions resulted in the desired 
coupling. 
 
 
 
 
Scheme 4.8. Coupling of mc fluorinated analogue to the vc-PABA fragment 
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The last fragment of the synthesis is the addition of the chemotherapeutic agent 5-
fluorouracil.This agent needs to be activated to be able to couple to the linker. To activate it, we 
attempted to couple it to 4-nitrophenyl chloroformate (4.23) using various bases but in all cases 
only starting material was recovered (Scheme 4.9). The relative low reactivity of 5-fluorouracil 
coupled with the instability of the chloroformate 4.23 are the possible reasons behind the failure 
of this reaction.  
 
 
 
 
 
Scheme 4.9. Coupling of 4-nitrophenyl chloroformate to 5-fluorouracil 
Since 5-fluorouracil wasn’t ideal for our synthetic route, we decided to use another 
fluorinated chemotherapeutic agent, gemcitabine. The coupling of gemcitabine with the 
chloroformate 4.23 proceeded in low yields of compound 4.25 (Scheme 4.10)). In this reaction, 
satisfactory conversion was observed by TLC but when purification by chromatography was 
attempted low yields resulted, possibly due to instability of the product on silica. Hence, for the 
purposes of our synthesis the crude mixture of this reaction will be carried forward to the next step.   
 
 
 
 
Scheme 4.10. Coupling of 4-nitrophenyl chloroformate to gemcitabine 
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4.1.3. Second Approach Towards Synthesis of Fluorinated Antibody-Drug Conjugates 
To address the issue with coupling the fluorinated mc analogue 4.12 to the rest of the linker 
we decided to modify our synthetic route to carry this step early in the synthesis. For this alternative 
approach, we disconnect gemcitabine from the linker first, next we disconnect the monofluorinated 
PABA group (Scheme 4.11). The next disconnection is of the citrulline amino acid and lastly 
valine is disconnected from the mc analogue 4.12.  
 
 
 
 
 
 
 
 
 
 
Scheme 4.11. Second approach towards synthesis of fluorinated linker 
The synthesis started with a coupling reaction of the mc analogue 4.12 with valine methyl 
ester (4.30), which proceeded in 35% yield (Scheme 4.12). The methyl ester was next saponified 
to the give the carboxylic acid 4.32 in 82% yield. The carboxylic acid was activated by coupling 
it to HOSu to produce 4.29 in 67% yield. The attempt to couple the activated carboxylic acid 4.29 
to citrulline was unsuccessful.  
 
109 
 
 
 
 
 
 
 
 
 
Scheme 4.12. Synthesis of fluorine tagged vc dipeptide 
 
4.2. Tetrafluorosulfanyl Group 
The tetrafluorosulfanyl (SF4) group is a novel, highly fluorinated group with potential 
applications in medicinal chemistry and as fluorinated probes. Typically, this group is synthesized 
through fluorination of sulfides using hydrofluoric acid or other similar fluorine sources (Scheme 
4.13a).187 These conditions usually results in over-fluorination due to the use of harsh fluorinating 
reagents. A recent advance in the synthesis of SF4-containing compounds was reported by 
Umemoto et al. in which thiols or disulfides form chlorotetrafluorosulfanyl (R-SF4Cl) compounds 
when treated with chlorine gas and potassium fluoride.188 The SF4Cl group can then react with 
fluoride salts to form the pentafluorosulfanyl (SF5) group,
188 or with alkenes or alkynes under 
radical conditions to form internal SF4 group (Scheme 4.13b).
189-190 
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Scheme 4.13. Known synthetic methods of tetrafluorosulfanyl containing compounds 
The bromotetrafluorosulfanyl (SF4Br) group is not known. In an attempt to access this 
group, we tried using bromine with fluoride salts in an analogous manner to the reported synthesis 
of the SF4Cl group. Various attempts with different solvents, sources of fluorine and bromine, 
different temperatures, use of crown ethers and molecular sieves failed to afford the desired 
product (Table 4.1). In most cases, the major product was the sulfinyl fluoride or the sulfonyl 
fluoride. 
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Table 4.1. Conditions used to access the SF4Br group 
 
 
Trifluorosulfanyl (SF3) containing compounds are intermediates in the proposed 
mechanism of SF4Cl synthesis (Scheme 4.14). Thus, SF3 compounds provide a good starting point 
for SF4Br synthesis. Attempts to further fluorinate these compounds using CsF/oxalyl chloride or 
CsF/Selectfluor failed. Alternatively, we tried alkylation strategies using Grignard or methyl 
lithium reagents, these reactions were also unsuccessful (Scheme 4.15).  
 
 
 
 
Scheme 4.14. Mechanism of SF4Cl formation 
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Scheme 4.15. Attempts to fluorinate/alkylate trifluorosulfanyl compounds 
 
Since oxidized sulfurs were the main product in our previous attempts, we endeavored to 
fluorinate sulfoxides using cesium fluoride and oxalyl chloride in an attempt to replicate the active 
species observed during sworn oxidation reactions. We tried dimethylsulfoxide and diphenyl 
sulfoxide in the presence and absence of bromine both at 0 oC and –78 oC (Scheme 4.16). But in 
all cases no major fluorinated product was observed. 
 
 
 
 
 
 
Scheme 4.16. Attempts to fluorinate sulfoxides 
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Next, we turned to the pentafluorosulfanyl group and ventured to defluorinate it. Since 
BBr3 has been reported to convert CF3 compounds to CF2Br compounds,
191 we were curious to 
see if a similar reaction would take place with SF5 compounds. Unfortunately, the only observed 
fluorine signal was that of the starting material (Scheme 4.17a). We also tried methyl lithium, but 
no reaction was observed. Lastly, several Grignard reagents were used, and they resulted in 
alkylation of the ring of p-nitropentafluorosulfanyl benzene but the SF5 group remained intact 
(Scheme 4.17b). The alkylation of the ring in p-nitropentafluorosulfanyl benzene using Grignard 
reagents has been reported by Beier and Vida.192   
 
Scheme 4.17. Attempts to defluorinate pentafluorosulfanyl compounds 
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